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Aim of the project 
AIM OF THE PROJECT 
The aim of this project was to study the potential of multi-analyte fluorescence 
immunoassay methods which utilise flow injection analysis, with a thiophilic gel as 
the solid phase immunoreactor. 
The research involved the following sections: 
I) Single analyte immunoassays: hydrocortisone, theophylline, albumin and 
transferrin. 
2) Dual immunoassay: albumin, transferrin. 
3) Multi-analyte fluorescence spectroscopy and multi-analyte immunoassays. 
4) Investigation of the binding efficacy of the thiophilic gels. 
5) Comparative studies using protein A or G immunoreactors. 
ii 
Abstract 
ABSTRACT 
Fluorescence immunoassays have been established for a number of years as 
valuable methods of analysis in clinical chemistry and other fields, being sensitive, 
safe, easy to use and available in a variety formats. Those in common use are 
normally single analyte assays. But in many cases (e.g. forensic drug screening, 
therapeutic drug monitoring, screening for cancer markers, monitoring of thyroid 
function, or the analysis of environmental pollutants) dual- or multi-analyte assays 
would be much more valuable, with the advantages of increased information 
content, savings in time and costs, and the elimination of some sources of sampling 
variance. Amongst all the labels used in immunoassays, only fluorescent groups 
offer realistic prospects of practicablemulti-analyte assays. 
This project has investigated single, dual- and multi- analyte fluorescence 
immunoassays using several spectroscopic and software methods to resolve 
multicomponent fluorescence emission or synchronous spectra. The assays have 
been based on flow injection analysis methodology, with solid phase reactors to 
effect the separation of antibody-bound and unbound labelled analytes. The use of 
solid phase reactors incorporating thiophiIic gels to bind antibodies has also been 
investigated: these stationary phases have the advantage that bound antibodies can 
be eluted by changes of ionic strength, rather than changes of pH. This allows the 
use of a much wider range of fluorescence labels, clearly important in multi-analyte 
assays, and it has thus proved possible to develop successful dual and triple analyte 
assays, with results that compare well with other independent methods. 
ab, anti ------------------ antibody 
ag ------------------------ antigen 
Notation 
cAMP ------------------- adenosine 3' 5' -cyclic monophosphate 
ACTH ------------------- pituitary adrenocorticotropic hormone 
BB ----------------------- binding buffer 
BSA --------------------- bovine serum albumin 
C.B, C.Blue ------------- Cascade Blue acetyl azide trisodium salt 
CNS --------------------- central nervous system 
3-D scan ----------------- 3-dimension fluorescence scan program 
EB ----------------------- elution buffer 
Notation 
EDAC ------------------- l-Ethyl-3-(3-dimethlyaminopropyl) carbodiimide) 
hydrochloride 
ECG --------------------- electrocardiogram 
EIA ---------------------- enzyme immunoassays 
Fab ----------------------- fragment antigen binding 
Fc ------------------------ crystallizable part 
FIA ---------------------- flow injecti,on analysis 
FIIA --------------------- flow injection immunoassays 
FITC --------------------- fluorescein isothiocyanate isomer I 
F4500IC ----------------- F4500 fluorescence spectrophotometer intracellular 
cation measurement program 
F-4500 ------------------- Model F14500 Spectrometer Hitachi 
fl. int. -------------------- fluorescent intensity 
GLC --------------------- gas liquid chromatography 
Hydrocortisone-21-HS hydrocortisone-21-hemisuccinate 
RSA --------------------- human serum albumin 
HPLC -------------------- high performance liquid chromatography 
6./'" ------------------------ interval wavelength of synchronous scan 
IDDM ------------------- insulin dependent diabetes mellitus 
iv 
LS-50B ------------------ LS-50B spectrometer Perkin Elmer 
NHS --------------------- N-hydroxysuccinimide 
NSB --------------------- non-specific binding 
PB S ---------------------- Phosphate buffer saline 
pk.a. --------------------- peak area 
pk.h. --------------------- pear height 
Ftlf\ ----------------------
sp f\ ----------------------
1l1)1\1 --------------------
ll-gel ---------------------
llLC: ---------------------
radioimmunoassays 
protein f\ 
therapeutic drug monitoring 
thiophilic absorbent gel 
thin layer chromatography 
llFtI1lC: ------------------ tetramethylrhodarnine isothiocyanate isomer Ft 
UV ----------------------- ultraviolet visible 
v 
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Chapter One 
GENERAL INTRODUCTION 
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Chapter 1. Introduction 
1.1 Immunoassays 
Immunoassays were developed in the 1930sas a technology in researches into 
immunological reactions [lJ. After Yalow and Berson described the principles of 
competitive immunoassay in 1959 [2], there has been an exponential growth in 
contributions to medicine and other life sciences. The technology now finds 
further applications in the forensic, veterinary, pharmaceutical, environmental and 
food sciences. Immunoassays are based on the determination of an antigen (or 
hapten), using the corresponding antibody as a reagent (sometimes these roles are 
reversed). They thus rely on the detection of the antibody-antigen reaction and 
exhibit great specificity, versatility, practicability and sensitivity. 
1.1.1 Classification of Immunoassays 
Immunoassays can be classified according to tIie type of the analysis, sample, assay 
system and conditions. 
• Immunoassays which require no label. 
• Immunoassays which require labels, which can be radioisotopic or non-isotopic 
assays with labelled antigen or antibody. 
• The reaction procedure can be competitive or non-competitive. 
• Assays may require or may not require a separation step (heterogeneous or 
homogeneous assays). 
1.1.2 Antigens 
An antigen is any foreign substance of natural or artificial origin that stimulates the 
production of a specific antibody in a animal body then the antigen is subsequently 
bound to an antibody in a specific immunological reaction. 
2 
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Any antigen may be considered as belonging to one of three classes (Table 1.1.1): 
nature, artificial and synthetic antigens. 
Table 1.1.1 Classes of antigens 
Class of antigen Origin 
Nature plants, bacteria, 
animals 
Artificial chemically modified natural 
antigens 
Synthetic chemically synthesis molecules 
Example 
blood cells, bacteria, 
viruses, proteins 
proteins, protein-hapten 
conjugates 
polypeptides, 
polyaminoacids, 
multichain aminoacid 
copolymers 
For functional sense, an antigen may be complete, or incomplete, complete antigen 
which also is referred to as an immunogen, the molecular sizes of complete 
antigens are normally very large proteins, glyco-, lipo-, nucleic-conjugates and 
polysaccharides. An immunogen has two basic properties: 1) immunogenicity 
which is the ability to induce an immune response; 2) specificity which is the ability 
to react with specifically antibodies. Incomplete antigen is called hapten, it only 
has the specific that specifically reacts with antibodies, but it has not got the 
immunogenicity that unable to induce the immune response. The molecule sizes of 
hapten are usually small, such as drugs. Hapten may be bound to a larger molecule 
(carrier) then it can be gain the immunogenicity to become immunogen. Proteins 
such as serum albumin, globulin, ovalbumin and even gelatine are most frequently 
used as the carriers. 
The properties of the antigen affect it's immunogenicity. The properties are 
physical (molecular weight, solubility, electric charge); chemical (structure, 
degradability) and biological (species remoteness). As far as physical properties 
are concerned, the relative molecular weight is the most important. Generally, any 
3 
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antigen must be a macromolecule and usually has molecular weight above 10,000 
Dalton, thus it is able to induce an immune response in a host, subsequently 
produces a specific antibody. From the chemical standpoint, antigens may be 
various biopolymers, particularly proteins and polypeptides. Proteins are the most 
potent antigens, this is because a protein has a big molecular weight and contains 
enough determinant groups on its' molecule surface. The determinant group(s) is 
a specifically functional chemical group(s) on the surface of the antigen which is in 
suitable conformation and available to bind to a receptor of an immunocompetent 
cell (refer to as a regulatory and effector lymphocyte), then the antigen is able to 
induce a immune response. The biological properties of an antigen, genetic 
diversity (species remoteness) is influence by its immunogenicity. Not all foreign 
substances are immunogens, i.e. carbon in the form of soot is foreign for the animal 
organism but does not induce an immune response, it is instead removed for the 
body by mechanisms of natural immunity (phagocytosis). Thus one property is not 
enough for a substance to become a antigen, a suitable combination of physical, 
chemical, and biological properties are required. 
Each macromolecule antigen contains several epitopes (antigenic determinants) 
t 
that can be distinguished by a specific antibody. An epitope is usually very small 
and normally consists of 5-7 amino acid. 
1.1.3 Antibodies 
1.1.3.1 Introduction 
Antibodies or immunoglobulins were officially defined by the WHO in 1969 [3] as 
"proteins of animal and human origin that are endowed with known antibody 
activity and which also include certain proteins related to antibodies in chemical 
structure and hence in antigenic specificity". Antibodies are a group of 
glycoproteins, present in the serum and tissue fluids of all mammals. They are 
produced by B lymphocytes in response to immunogenic foreign molecules 
4 
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(antigens). Usually in human blood serum the concentration of antibodies is 12 -15 
mg / ml, the molecular weights being from 150,000 to 970,000 Dalton. 
In most higher mammal antibodies can be divided into five classes named IgG, 
IgA, 19M, IgD and 19E, differing from each other in size, charge, amino acid 
composition and carbohydrate content. Each of the five classes has similar sets of 
light chains but an antigenically distinctive set of heavy chain in constant region. 
The 19G class which, can be further divided into four subclasses, is the major 
immunoglobulin in most higher mammals (in normal human serum accounting for 
70-75% of the total immunoglobulin pool) and the one most often used in 
immunoanalytical techniques. 
1.1.3.2 Structure of Antibody 
Intensive studies of antibody structure began in 1950 by Porter, who split the IgG 
molecule into three fragments with the aid of the proteolytic enzyme papain [4], 
and in 1960' s structural studies of immunoglobulin began to accelerate [5-8J. IgG 
may be considered as a typical example of the basic antibody structure (Fig. 1. 1.1). 
IgG has a two-fold axis of symmetry, the structure resembles a letter Y: the 
molecule having two identical heavy (H) polypeptide chains (each 50,000 Dalton), 
and two identical light (L) (each 25,000 Dalton) chains linked together by 
disulphide bonds. About 112 of each light chain and 114 of each heavy chain are 
variable regions (VL , VH), because the order of amino acids in this region which is 
close to the amino acids (N) terminus and dependent on the specific antibody, the 
rest of chains are called constant region (CL, CH) which are close to carboxy (C) 
terminus and the order of the amino acids in these region are mostly constant. 
After papain digestion IgG which can be divided into three fractions: Two antigen 
binding, Fah-fragments (fragment antigen binding) and one constant, non-binding 
fraction Fe-fragment (crystallizable part). 
5 
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1.1.3.3 Polyclonal and Monoclonal Antibodies 
Polyclonal antibodies are produced by a number of Iymphocytes, so the antiserum 
contains a range of antibodies. In the highly specific immunoreactions, this 
heterogeneity response would give conflicting experimental results in various 
laboratories. Monoclonal antibodies are produced by a single B lymphocyte, so 
they are homogeneous. Since Kohler and Milstein in 1975 [9] introduced the 
hybridoma technique for producing monocJonal antibodies, they have replaced 
polycJonal antibodies in many assays, having advantages in specificity and low non 
specific binding. 
1.1.3.4 Antigen-Antibody Reactions 
An antibody (Ab) specifically binds to an antigen (Ag) to form an antigen-antibody 
complex which are linked by hydrogen bonds, electrostatic forces, van der Waals 
forces, hydrophobic bonds and non-covalent bonds (Fig. 1.1.2) . For an antigenic 
determinant and an antibody can combine: 
• there must be suitable groups on complimentary parts of the antigen and 
antibody. 
• the over all shape of the antibody combining site must fit the antigen, to allow 
the number of bonds mentioned to form simultaneously. 
The Scatchard modeJ( 1-1) is the most widely used mathematical approach to the 
quantitative description of the multiple equilibrium taking place when an antibody 
binds reversibly to a ligand molecule( antigen or analyte). This model focuses on 
the law of Mass action shows the antibody affinity constant to an antigen (1-2) 
[10-11]: 
6 
Ab + Ag <=> AbAg 
K = [AgAb] 
[Ag] [Ab] 
[Ag] = antigen concentration 
[Ab] = antibody concentration 
[AbAg] = antibody antigen complex concentration 
Chapter 1. Introduction 
(1-1) 
(1-2) 
K = the equilibrium association constant (affinity constant), usually 10.8 _10.11 
Vmol 
Antigen-antibody reactions ate reversible and affected by pH, temperature, ionic 
strength of the solution, reaction time and the ratio of the antibody to the antigen. 
Fab r~glon 
Olsulflde bondS V H Variable heavy chain 
pg;;:;; U:ii;;;>;:,-] Heavy chain 
V l variable light chain 
Light chain 
C Carboxy terminal C H Constant heavy chain 
N Amino terminal 
C L Con Slant light chain 
Fig.1.1.1 The structure of an antibody. 
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'b d antI 0 y t" gen an , 
~ ;,;.' .... H .... ..2 hydrogen 
bonding N ............. H N 
electrostatic T T 
.-+ . -+ 
Van det Waals 
+ -. + -. 
hydrophobic ..... /"-. ....-
I water exclvded I 
,-
Fig.1.1.2 The principle of an antigen-antibody reaction. 
1.1.3.5 Antibody Purification 
Polyclonal antibodies are usually isolated from blood serum and only a very few 
from other body fluids. Methods providing antibodies of varying purity and 
immunochemical activity, basic techniques include: 
non-specific techniques, such as :1) salt precipitation -e.g. ammonium sulphate, 
2) electrophoresis -e.g. papers, agarose, 
3) ion-exchange chromatography-e.g. 
CM-Sephadex, 
4) gel filtration -e.g. Sephadex G-25, 100 and 
specific methods, such as: immunoaffinity chromatography using Protein A or G. 
1.1.4 Design of Immunoassays 
Immunoassays can be simplified into two main groups: heterogeneous and 
homogeneous assays, depending on whether a separation step is required. 
8 
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1.1.4.1 Heterogeneous Assays 
Heterogeneous assays are based on physical separation of free labelled antigens 
from antibody-bound antigen or unbound labelled antibody from an antigen-bound 
fraction before measurement. Such assays reduce the background interference 
derived from other sample components enabling the levels of detection of the assay 
to be improved. Some common separation techniques include precipitation, 
absorption and solid phase separations with affinity or other media. Solid phase 
sandwich techniques and competitive assays (reagent limited) are frequently used 
in the heterogeneous assays. Competitive assay is relies on the competition 
between the labelled and unlabelled analytes for a limited amount of antibodies. In 
this project the competitive assays would· be developed and scheme of a 
competitive assay is shown in Fig.1.1.3. 
1.1.4.2 Homogeneous Assays 
Homogeneous assays take place completely in one phase, i.e. when the antibody-
antigen reaction can be measured without physical separation of the free antigen or 
antibody from the unbound fraction. The analyte concentration in the sample can 
be monitored directly from changes in properties resulting from the reaction, e.g. in 
the fluorescence properties of the labelled antigen or antibody. Such assays are 
very rapid, simple and more straightforward to automate. Some common 
techniques are fluorescent polarisation methods, fluorescence quenching assays and 
fluorescence energy transfer immunoassays [12-14]. But homogeneous assays can 
be susceptible to matrix interference e.g. presence of endogenous fluorescence 
materials. 
Some of the comparisons between heterogeneous and homogeneous assays are 
shown below: 
9 
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Homogeneous Heterogeneous 
Simple to perform Complicated assay, some are 
time and labour intensive 
Limited sensitivity 
Easy to automate 
Sensitive to interference 
-< • H~ '1' • 
+ • + 
High sensitivity 
More difficult to automate 
Less sensitive to matrix 
~ 
• ..... 
.....- -<t*~ • '1' H.~ 
-< • '1' • H~ • '1' 
Antibody Analyte In labeffecl Separation 01 antib()dy-bound and free fractions e.g. by 
sample analyte precipitation of antibody, centrliogatlon and decantatlon of free 
(tracer) frectlon 
Fig.l.1.3 Schematic diagram of a competitive immunoassay. 
1.1.5 Detection Methods for [mmunoassays 
1.1.5.1 Unlabelled Immunoassays 
These type of immunoassay include immunoelectrophoresis and 
immunoprecipitation. They can be performed only on large antigen-antibody 
complexes, i.e. proteins and at high concentrations, so sensitivity and selectivity are 
limited. 
10 
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1.1.5.2. Radioimmunoassays (RIAJ 
In labelled immunoassays the labels can be attached to antigens or antibodies. 
Such immunoassays can be categorised as isotopic or non-isotopic, the non-
isotopic assays including enzyme, fluorescence, chemiluminescence and metal 
immunoassays. 
Immunoassays which employ radioactive isotopes (isotopic assays) have been 
rapidly developing since their introduction by Berson and Yalow [2] in 1959. They 
demonstrated the presence of insulin antibodies in human serum using 1131 labelled 
insulin. This promoted a great deal of research into other radioisotopic labels for 
immunoassays. The commonly used isotopes are 1125, C14 and H3. 
Radioimmunoassays offer extremely sensitive and precise methods [15]. But they 
have certain drawbacks: radiation ca~ses health hazards, the isotope determination 
methods require relatively expensive instrumentation and reagents and the use of 
radioactive isotopes also requires a special permit and special laboratory areas. 
Due to these problems non-radioactive labels are now becoming more popular 
detection system in immunoassays. 
1.1.5.3 Enzvme lmmunoassays (EIA) 
The use of enzymes as non-isotopic labels in immunoassays has developed since 
the mid-60's [16]. The most common types of EIA are the enzyme-linked 
immunosorbent assay (ELISA) and the enzyme-monitored immunotest (EMIT). 
More than 25 different enzymes have been used in immunoassays, but only three 
enzymes, such as alkaline phosphates(ALP), ~-D-galactosidase(BG) and 
horseradish peroxides(HRP) have been extensively used in both research 
applications and the commercial environment. An enzyme labelled immunoassay 
use either a labelled analyte or antibody. Enzymes have advantages in highly 
activity at low substrate concentrations providing sensitivity, highly specific both in 
11 
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the reaction catalysed and in the choice of substrates; reactions are stable under 
routine storage and assay conditions and equipment which is relatively inexpensive. 
But there are a variety of problems inherent in enzyme immunoassays. Enzymes 
are proteins, some with a relativity large molecular weight, up to 500,000 Dalton, 
(e.g. ~-D-galactosidase) which can cause steric hindrance effects, the detected 
signal is very much dependent on the chemical and the physical conditions, such as 
incubation time, pH effects, temperature. Some enzymes are suffer from inhibition 
by products or environmental factors. The principles and practical in the use of 
enzyme labels were reviewed by Ti jssen [17]. DV-visible spectrometry, 
fluorometry, chemiluminescence and electrochemical methods can all be used for 
detection in enzyme immunoassays. 
1.1.5.4. Fluorescence Immunoassays(FIAJ 
Fluorescence immunoassays are based on using a fluorophore labelled analyte or 
antibody instead of a radioisotope label. Fluorescent labels offer safe, stable, cheap 
reagents with rapid, sensitive and selective detection, fluorescence also can be 
measured quickly and simply with small samples and relatively inexpensive 
instrumentation. Labelling antibodies with fluorescent probes as a qualitative 
staining technique was reported in 1941 [18]. Fluorescence irnmunoassays as 
quantitative analytical methods have been intensively developed since the early 
1970's. However, in practice its sensitivity significantly decreases because many 
proteins and components of biological material may also fluorescence and causes 
an increases the background fluorescence level, therefore the sensitivity of FIA 
varies between 10.9 and 10.12 moIlI. There are number of reviews and papers 
describing common applications of PIA, including fluorescence polarisation 
methods (FPIA) [19-20], time resolved methods (TR-FIA) [21-23], fluorescence 
quenching methods [24], fluorescence enhancement methods [25] and solid phase 
methods [26-28]. 
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Fluorescence immunoassays can also be classified into heterogeneous and 
homogenous assays, depending on whether a separation step is required. 
Heterogeneous fluorescence immunoassays and solid phase assays will be 
described in sections 1.4.3-1.4.4. 
1.1.6. Multi-Analyte Immunoassays 
Immunoassays traditionally are performed as discrete tests, i.e., each assay is only 
able to analyses one analyte. An alternative option is multi-analyte immunoassays, 
in which two or more analytes are measured simultaneously in a single assay. The 
advantages of simultaneous multi-analyte analysis are: 
• work simplification - the number of assays required for the assay is reduced, 
and also reduction in the number of pipetting, washing, and decanting operations. 
• increase in test throughput - the time required for a multi-analyte assay is 
generally same as for the individual assay, so it is saving time and increasing test 
throughput. 
• reduction in the overall cost per test - the time and labour component of the 
overall cost per test is reduced compare to the same tests performed on a single 
assay. 
Generally, the multi-analyte immunoassays can be classified into two main formats: 
1) assays based on more than one label, 
2) the assay based on spatially separated test zones 
these are shown in Table 1.1.2.-1.1.3 and Fig. 1. 1.3.[29] 
In 1989, Ekins [30] described the development of multi-analyte immunoassays as 
an important advance in medicine, pharmaceutical, food industries and 
environmental research. In Table. 1.1.4 is a multi-analyte immunoassay protocol 
which shows some common situations for analytes which are grouped in panels. 
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However, finding combinations of different labels has proved problematical and has 
not progressed beyond two labels, e.g. two radioisotopic labels, 1125 and 1131 [31] 
or 1125 and COS7 [32-33] have been combined in a dual analyte assay for lutropin 
and follitropin; for folate and cobalamin. In non isotopic immunoassays, p_ 
galactosidase and alkaline phosphates have been combined in a dual assay for 
phenobarbital and phenytoin [35]. Fluorophore labels provide a broad range of 
distinguishable fluorescence signals. Lutropin and follitropin have been 
simultaneously measured in serum by dual label time-resolved immunofluorimetry 
with Eu3+ and Tb3+ respectively [36]. 
Table.1.1.2 Combinations oflabels used in dual label multi-analyte immunoassays 
Label 1 (detection method) Label 2 (detection method) reference 
1125 (scintillation counting) 
1125 (scintillation counting) 
p-Galactosidase 
(fluorometry) 
p-Galactosidase 
(fluorometry) 
Eu III (TRF) 
Eu III (TRF) 
CO2(CO)6 (FT -ir) 
Radioisotope labels 
Illl (scintillation counting) [31] 
COS7 (scintillation counting) [32-33] 
Enzyme labels 
phosphodiesterase (fluorometry) [34] 
alkaline phosphates (photometry) [35] 
Fluorescent labels 
Tb III (TRF) [36] 
, 
SmIII (TRF) [37] 
Metal labels 
Cyc!opentadieny Mn(CO)l (FT -ir) [38] 
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Table.1.1.3. Spatially separated test zones fonnats for simultaneous immunoassay. 
Fonnat Reference 
colored latex particles [39] 
two-sided dipstick [40] 
microspots [41] 
macrospots [42] 
zones on a membrane [43] 
Table. 1. 1.4. Diagnostically related groups of test suitable for the simultaneous 
immunoassays fonnat 
Type of testing 
allergen testing 
blood banking 
dried blood spot analysis 
drugs of abuse testing 
dual and triple testing 
fertility testing 
example 
19E and 19G antibodies 
antibodies to HIV -1, HTL V-I 
17 -a-Hydroxyprogesterone, 
thyrotropin, immunoreactive trypsin, 
creatine kinase MM isoenyzme 
cocaine, amphetamines, opiates 
AFP, free-beta, hCG; AFP, estriol, hCG 
lutropin, follitropin, hCG, prolactin 
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1.2 Fluorescence Spectroscopy 
1.2.1 Principle of Fluorescence Spectroscopy 
When a molecule absorbs a quantum of radiation of sufficient energy, it attains an 
excited state with a different electronic distribution. This extra energy is often 
quickly dissipated to surrounding molecules. If any molecule emits radiation, this 
is called luminescence, and luminescence is divided into several categories 
according to the energy source used for excitation of the luminescent molecule. 
Fluorescence is a luminescence phenomenon. When a molecule is excited by 
photons, its electrons are raised from a low energy level to excited levels. If 
the excited state is sufficiently stable, after ca. 10-8 s the electrons may return 
to its ground state by emitting radiation at longer wavelength than the 
excitation wavelength. The phenomenon is called fluorescence, but if delayed, 
the process is called phosphorescence, (Fig. 1.2.1). 
Fluorescence involves transitions from the lowest vibrational level of the first 
excited singlet to the ground state, giving rise to a typical transition distribution 
and fluorescence emission spectrum. Because the emission almost takes place 
from the lowest vibrational level of SI, the shape of the emission spectrum is 
independent of the excitation wavelength. If the vibrational levels are similarly 
spaced in the ground state singlet and in the first excited singlet, the emission 
spectrum is approximate a mirror image of the absorption spectrum, with the 0-0 
transition as the plane of symmetry [1] (Fig.l.2.2). 
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A modified version of the Beer-Lambert law relates the fluorescence intensity, 1ft 
to concentration [2] is: 
1/ = <I> (10 -I) (1-3) 
where ID is the power of the beam incident upon the solution, I is the power after 
traversing a length b of the medium. <I> is the quantum yields of the process. In 
order to relate If to the concentration of the fluorophore, using the Beer-Lambert 
law in the form: 
..!.= lO-,bc 
1, 
(1-4) 
where € is the molar absorptivity of the fluorescent molecules, and €be = A, the 
absorbance. By substitution of equation (1-4) into equation (1-3), it has: 
The exponential term can be expanded as a series to 
1/ = <1>10 [2.3€be _ (2.3€ be)2 
2! 
+ (2.3€be)3 ... ] 
3! 
(1-5) 
(1-6) 
When €be = A < ca. 0.05, all of the higher order terms in the brackets become 
small, so it may write: 
1/=2.3 <I> €belo (1-7) 
In practice only a fraction, K, of the emitted light is detected, so: 
I/=2.3 K<I> ebcIo (1-8) 
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Where, K is the quantum efficiency, 
<I> is the quantum yields, 
I is the incident radiant power, 
E is the molar absorptivity, 
b is the path length of the cell, 
c is the molar concentration. 
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Fluorescent molecules can be characterised by their absorptivity, absorption 
spectra, emission spectra, quantum yields, and fluorescence lifetimes. 
Furthermore, the fluorescence is highly dependent on the environment, such as 
temperature, solvent polarity, pH, and concentration. 
The main components of any fluorescence instrument are a source of excitation 
radiation, a primary filter or monochromator, a sample cell, a secondary filter or 
emission monochromator, a detector, and data readout. This is simply illustrated 
in Fig.l.2.3. 
Fluorescence provides a selective and sensitive detection system that can be 
applied in many fields. A principal area is biological science. Every year a large 
number of papers describing such applications, appear in biochemistry and clinical 
chemistry journals. Fluorescence spectroscopy as a tool has been very rapidly 
developed in recent years. 
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1.2.2 Multi-Fluorescence Labelling Spectroscopy 
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electronics 
and recorder 
detector 
A multi fluorescence labelling experiment entails the deliberate introduction of two 
or more fluorophores to simultaneously monitor different fluorescence spectra in a 
single experiment. Fluorescence as a chemical label in inununoassays which is well 
known and offers a wide range selective technique with several accessible 
experimental variables. Utilising traditional fluorescence spectroscopy techniques 
for immunoassays, it would be limited by the simultaneous detection of different 
labels in the fmal step of the procedure. Because the fluorescence signal isolation 
and data analysis are facilitated by maximising the spectral separation of the 
multiple emissions 
1.2.2.1 Synchronous Excitation Fluorescence Spectroscopy 
This technique will be described in detail in a separate section 1.2.3. 
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1.2.2.2 The Quant Computer Program 
Quant+ computer program, specifically combined with the LS-SO fluorescence 
spectrometer (Perkin Elmer), is a chemometric software package. It provides a 
choice of multivariate calibration algorithms (PeR-principal components regression 
and PLS-partial least squares techniques) and is designed for multi-component 
spectroscopic analysis. 
1.2.2.3 3-Dimension Scanning (3-DJ 
The 3-dimensional fluorescence technique is able to measure the value of a 
fluorophore from a three dimensional plot. The spectra, in which one axis 
represents the excitation wavelength, a second axis represents the emission 
wavelength, and the third axis represents the intensity gives a complete description 
of the fluorescence behaviour of a component. If over a use7selected wavelength 
range. The data are obtained on a conventional spectrometer by (e.g.) making 
repeated emission scans at incrementally altered excitation wavelengths with 
subsequent data processing. 
1.2.2.4 F-4S00 Fluorescence Spectrophotometer Intracellular Cation 
Measurement 
The intracellular cation measurement (F-4500IC) computer software is specifically 
designed for the Hitachi F-4500 fluorometer. The principle of the program is based 
on conventional (fixed wavelength) fluorescence spectroscopy, but it is able to 
very rapidly up to 4 different fluorescence spectra. In a complex mixture, the 
excitation and emission wavelengths are set in order (e.g. for 4 fluorophores), then 
all the individual spectra will be presented on the screen. 
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1.2.3 Synchronous Fluorescence Spectra 
Fluorescence spectroscopy with its excellent sensitivity has provided an analytical 
tool for qualitative and quantitative analysis in many areas. In conventional 
fluorescence spectroscopy, an emission spectrum is generated by scanning the 
emission wavelength, Aem, as the sample is irradiated at a single excitation 
wavelength, Aex. Analogously, an excitation spectrum results from scanning the 
excitation wavelength while recording the emission signal at a single wavelength. 
But analysis of a complex mixture of fluorescent compounds sometimes cannot be 
satisfactorily achieved by using excitation at fixed wavelengths selected for 
individual compounds. One technique which offers improved selectivity for 
fluorescence analysis without having to sacrifice simplicity is the synchronous 
excitation technique. The idea of synchronous excitation fluorescence was first 
introduced by Lloyd [3] who applied it to mixtures of polynuclear hydrocarbons 
commonly produced in the pyrolysis and combustion of organic materials. 
1.2.3.1 Principles of Synchronous Fluorescence 
The excitation monochromator is set at wavelength A. and the emission 
monochromator is set at (A + ~A); these are then scanned synchronously i.e. at the 
same rate, while recording the fluorescence intensity. A constant wavelength 
interval ~A between the excitation and emission wavelengths is normally, but not 
universal used. A more complete the theory and the principle of synchronous 
exaction spectroscopy techniques are reviewed in references [4-8]. The scheme of 
the principle of the synchronous techniques are shown in Fig 1.2.4. 
Synchronous fluorescence spectra are recorded as fluorescence intensity. The 
intensity of the synchronous signal has been shown to have the following 
expression: 
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Where, c is the concentration of the analyte, 
b is the path length, 
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(1-9) 
(1-10) 
E ('A. ) is the intensity distribution pattern of the excitation, 
x ex 
Em( \x + D.'A. ) is the intensity distribution pattern of the emission and 
k is a characteristic luminescence constant which includes the instrumental 
geometry factor and related parameters. 
This equation clearly shows that the synchronous spectrum depends upon both the 
emission and excitation spectra. The fluorescence signal is measured only when 
excitation and emission accrue at the selected D.'A.. From Fig. 1.2.5 [9] it can be see 
that the synchronous spectrum is much simplified compared with the excitation and 
emission spectra. 
1.2.3.2 Wavelength Interval (D.'A.J 
In general, the main difficulty encountered with the synchronous fluorescence 
technique is choice of a best D.'A. value, because it defines the shape and bandwidth 
of the synchronous spectrum. For example, if D.'). is small, the signal will be 
produced only in the limited range where the fluorescence excitation and emission 
bands overlap and if D.'A. gets larger the signal will be extended over a greater 
spectral range. Its shape and bandwidth are dependent on the total wavelength 
distribution of the analyte excitation and emission spectra. 
For qualitative and quantitative trace analysis, the goal is to investigate how the 
synchronous spectroscopy technique can be applied to obtain not only spectral 
signatures from complex samples but also specific information from individual 
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analytes of interest [8]. The optimal value of 11'A can be estimated from a three 
dimensional plot [10] (see above). This gives a complete description of the 
fluorescence behaviour of a compound. Also,. Vo-Dinh [8] has pointed out that if 
a compound has a small Stokes' shift, the 11'A value provides a single peak with the 
most intense signal and the narrowest half-width. 
1.2.3.3 Analytical Characteristics 
Synchronous fluorescence spectra have a narrow spectral bandwidth as a result of 
the multiplicative effect of the two functions, excitation and emission intensity, 
increasing and lor decreasing simultaneously while both 'Aex and 'Aem are scanned. 
Spectral simplification is another attribute of the synchronous technique. The 
emission of each individual compound is often simplified to a single band, so the 
interference with the emission from other species is greatly reduced if a suitable 11'A 
is selected. 
1.2.3.4 Inteiference with Synchronous Spectra 
The limitations of synchronous fluorescence spectroscopy are the same as for other 
luminescence techniques, such as intermolecular interactions, quenching and 
energy transfer, Rayleigh and Raman scattering, etc. Rayleigh scattering occurs 
from an elastic interaction between the excitation light and the solvent molecules, 
so a small 11'A interval may produce significant stray light. Raman scattering is also 
an interaction between the excitation light and the solvent, but induces a normally 
red shift in wavelength so is usually not a major problem in synchronous 
measurements. Use of Raman peaks as a measure of the purity of fluorescence 
grade solvents has been reported by L1oyd[11J. 
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1.2.3.5 Analytical Applications 
Synchronous fluorescence spectroscopy is a fingerprinting tool which has also been 
applied to the quantification of multicomponents. The first application of 
synchronous fluorescence spectroscopy was for measuring mixtures of 
benzo[k]fluoranthene, benzo[a]pyrene and perylene[4]. John and Soutar [12] used 
synchronous fluorescence to investigate crude oil samples. Clark et. al. reported 
the use of synchronous scanning spectroscopy for pharmaceutical applications 
[13]. Another example of the practical application of the synchronous fluorescence 
technique was reported by Vo-Dinh [8], who described in detail the analysis of a 
mixture of five PAHs (Polycyclic Aromatic Hydrocarbons). The conventional 
fluorescence spectrum revealed several peaks, so this mixture was not simple to 
analyse. But the synchronous excitation technique resu1ted in a series of 
exceptionally well-resolved peaks, the synchronous signals for each individual 
component ofthis mixture (Fig. 1.2.6). Synchronous spectroscopy may thus offer a 
simple method for the analysis of a complex mixture of fluorophores. 
, 29 
Chapter 1. Introduction 
1 I @ 81 :;1/\ I , 
2 I <9 © I ~I /\1 
, 
~i:J)..~ 
;;\ A I 3 e El , 
Fig.l.2.4 The principle of the synchronous technique. 1) is an excitation 
spectrum, 2) is an emission spectrum and 3) is a synchronous signal. 
('tCIU.1ION ____ {I fUKIFlESC(H((_ .... I" 
s~cctFlUN , s"o.ur.; 1 • 'SlN!;It.I)NOuS ~ • 1'\ I : 1 $!tlnt I1 1 I • , I I 1 00 1 , 
I " J i : J I 
,-..1 I 
· 1 , 1 I I 
· / I ... 1 . , , 
# 
.L..LW=-, 
..l..J..J 0 • 
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Fig.1.2.6 Conventional fluorescence spectrum of a mixture of naphthalene, 
phenanthrene, anthracene, perylene and tetracene (left). Synchronous spectrum of 
the mixture (right) (ref. Vo-Dinh, [8] ). 
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1.2.4 Fluorescence Conjugation 
One of the essential characteristics of fluorescent labels is a stable chemical link 
between the fluorescent label (which must retain its fluorescence in the resulting 
conjugate) and the molecule to be labelled. 
The structural features are important for fluorescent labels, these include rigidity, 
planarity and the general extent of the conjugated double bond system, from Fig. 
1.2.7 it can be seen that fluorescein is fluorescent, but phenolphthalein is non-
fluorescent. Pringsheim [14] pointed out that the presence of fused of aromatic 
rings may be one characteristic of fluorescent labels. 
Generally, the characteristics of fluorescent labels for protein labelling are as 
follows[15]: 
• A fluorophore should possess chemical groups that form stable covalent bonds 
with protein molecules. 
• The fluorescence efficiency of the dye must be high and should decrease as little 
as possible after conjugation to the protein. 
• The fluorescence wavelength or colour of the conjugate should differ 
significantly from the background signal from the solvent or the tissue sample 
(in fluorescence microscopy). 
• The conjugate should be stable under normal storage conditions and not differ 
materially in its properties from the unconjugated protein 
• The conjugation procedure should be as simple and short as possible. 
31 
Chapter I. Introduction 
Fluorescein Phenolphthalein 
Fig.I.2.7 The structures of fluorescein and phenolphthalein. 
1.2.4.1 Coupling and Purification of Conjugates 
To couple a fluorophore to a protein, it needs a reactive group such as sulfonyl 
chloride(R-SOzCI), isothiocyanate (R-N=C=S), and carboxylic acid group (R-
COOH), etc. Proteins contain several chemical groups that react with 
fluorophores. These include thiol, amino, and hydroxyl groups as well as the free 
amino and carboxylic acid termini. 
Many conjugation procedures have been reported, the most common type being 
conjugation of fluorescein isothiocyanate to e-amino groups of the lysine residues. 
The reaction [16] occurs at alkaline pH (Carbonate or bicarbonate buffer pH ~ 9). 
This is because the amino group of the lysine residues reacts with some of reactive 
fluorophore groups (e.g. with the sulphonyl chloride) at pH 8.5-11. And the 
number of fluorophores bond to the protein depends on the ratio of fluorophores 
to protein, reaction time, and salt concentration. 
When a conjugation is complete, the reaction mixture contains several unwanted 
components. Several methods have been developed to purify the conjugates. Gel 
filtration chromatography is the most commonly used technique. 
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1.2.5 Fluorescent Label 
1.2.5.1 Cascade Blue Derivatives 
Cascade Blue dyes are a group of fluorophores based on pyrenyloxytrisulfonic 
acid, in Fig. 1.2.8: R is either a carboxylic acid, an activated ester, or a substituted 
amide that is further modified to provide chemically reactive functional groups. 
The three sulfonic acids groups ensure that the fluorophores are water soluble. 
Therefore, Cascade Blue dyes can be used as fluorescent probes and labels for 
proteins, antibodies, enzymes, drugs, hormones. nucleotides, nucleic acids, 
polysaccharides, lipids, or other biomolecules, as well as cells, tissues, and natural 
or synthetic polymers. 
Cascade Blue derivatives exhibit absorption maxima at 374-378 urn and 399-403 
urn, with the emission maximurn in the range 422-430 urn. They have narrow 
spectral bandwidths and smaller Stokes' shifts than other reactive fluorophores in 
this spectral range, but these spectral range are sufficiently different from 
fluorescein to permit the simultaneous determination of both dyes. This offers 
potential advantages in simultaneous and multicolour applications (Fig. 1.2.9). 
The Cascade Blue derivatives exhibit .a number of useful properties and advantages 
these include [17]: 
• Narrow emission band, with little spectral overlap with fluorescein (FITC), 
• High extinction coefficients and quantum yields, 
• High solubility in aqueous media, 
• Low sensitivity to pH, 
• Low toxicity, 
• Reactivity with many of the functional groups found in biomolecules. 
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1.2.5.2 Fluorescein Isothiocyanate (FITC) 
Fluorescein derivatives are a group of dyes which have been very well known since 
they were reported several decades ago. Fluorescein isothiocyanate (FITC) is a 
typical example of the fluorescent derivative reagents for the covalent labelling of 
proteins, and it has been commonly used as a label and tracer in biochemistry and 
fluorescence immunoassays. Its basic structure is shown in Fig. 1.2.8. The 
functional isothiocyanate group (R-N=C=S) makes it very reactive with arnines and 
has high stability in water. Its excitation wavelength is at 495 nm and the emission 
wavelength is at 525 nm. The reactive form is water soluble (above pH 5). FITC 
absorbance is significantly quenched below pH 7. FITC's quantum yield is quite 
high, even though it is quenched by more than 50% on conjugation with proteins. 
In summary FITC is [18-19]: 
• A very good low molecular weight fluorophore available with high fluorescence 
yield. 
• A water soluble and stable fluorophore. 
• Easily conjugated to proteins. 
• Highly pH dependent fluorophore. 
o 
11 R= -c-N, 
Fig. 1.2 8. The structures of Cascade Blue (left), and FITC (right). 
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Fig. 1.2.9. The spectra of Cascade Blue and FITC. Excitation wavelength of 
C.Blue is at 405 nrn (A), emission wavelength of C.Blue is at 430 nrn (B); 
excitation wavelength of FlTC is at 495 nrn (C), and emission wavelength of FITC 
is at 525 nrn (D). 
1.2.5.3 Rhodamine Isothiocyanate (RITe) 
This group of dyes has a similar chemical structure and reactive group (R-N=C=S) 
to FITC, so is also widely applied as labels or tracers in biochemistry and 
fluorescence immunoassays. Their excitation wavelengths are close to 550 nrn, 
and their emission wavelengths 570-620 nrn. The most common members are the 
tetramethylrhodarnines, e.g. the reactive isothioyanate-TRITC. The fluorescent 
intensities of rhodarnines are lower than FlTC, but their spectra are not affected by 
changing the pH between 4 and 10 [18-19], this is an important advantage over 
fluorescein for many biological applications. 
1.2.5.4 BODIPY Derivatives 
BODIPY dyes show fluorescein-like spectra when used to generate fluorescent 
conjugates of proteins, nucleotides, etc. Their emission wavelengths range 
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between 400 run and over 650 nrn. Individual BODIPY dyes are introduced in 
reference [20]. 
1.2.5.5 Cy5 Fluorophore 
Cyanine derivatives are long wavelength (far-visible and the near-infrared spectral 
regions, 600-1000 nrn) fluorophores [20], so suffer less from background and 
interference effects than UV/visible fluorophores. Cy5 has excitation and emission 
wavelengths at 650 run and 670 run respectively. It is available as an amino-
reactive and water soluble fluorescent label for use in immunoassays [21] and other 
applications. 
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1.3 Flow injection Analysis (FIA) , 
1.3.1. Principle of Flow Injection Analysis 
Since flow injection analysis (PIA) was first developed in 1975 by Ruzicka and 
Hansen[I], many papers have described the development of its theory and 
applications [2-6]. PIA is now widely used in clinical chemistry, biochemistry, 
immunoassays and pharmaceutical analysis. PIA allows automation by injection of 
a liquid sample into a non segmented carrier stream of liquid. The sample is 
transported in conditions of controlled dispersion towards the detector, to measure 
some physical properties, e.g. absorbance, fluorescence. PIA provides a simple, 
rapid and precise method of handling small sample volumes, and the analytical 
parameters also can be easily controlled. These characteristiq make it particularly 
useful in immunoassays. Evans [7] has developed a fully automatic measurement 
of phenytoin by fluorescence flow injection immunoassay. 
In short, PIA presents four essential features: 
-unsegmented flow; 
-direct injection; 
-controlled dispersion; 
-reproducible operational timing. 
A flow injection system contains of five basic parts: 
• A propelling unit (e.g. peristaltic pump) - which produces the flow of one or 
more solutions, the solutions either containing a dissolved reagent or merely acting 
as the carrier(s). 
• Injection valve - consisting of a loop enabling a fixed volume of a measured 
sample to be injected in to the flowing steam. 
• Switching valve - used to control the nature ofthe stream through the colunm. 
• A column/solid phase reactor - the reaction area of the system, with or without 
additional process. 
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• A flow cell - accommodated in a detector (e.g. fluorometer or spectrometer) 
which transduces properties of the analyte into a continuous signal to a recorder or 
PC. 
A typical PIA signal is shown in Fig. 1.3.1. This may be measured in the form of 
peak high(H) or area(A). The essential features are as follow (Fig. 1.3.2): 
• Peak high H or peak area A - which is related to concentration of sample, 
• Residence time T - the time from injection to the maximum signal; Travel time 
Ta - is the period elapsed or injection to the start of the signal; t' = T - ta' 
• Return time T - is the period between the appearance of the maximum signal 
and the return to the baseline, 
• Baseline to baseline !:J.t - is the interval between the start of the signal and its 
return. 
1.3.2 Flow Injection Immunoassays (FIlA) 
Both homogenous and heterogeneous flow injection immunoassays reviewed by 
Gii bitz [8]. In a heterogeneous flow injection immunoassay system, the carrier 
stream transports the sample onto a solid phase reactor where the 
immunoreaction or a physical separation takes place before the analyte(s) is 
detected: this offers accelerated binding kinetics, because there is a very high 
surface area to volume ratio in the immunoreactor, the effective concentration of 
capture antibody being extremely high, and because the binding reactions do not 
have to rely on passive diffusion to bring reactants together, the flowing stream 
actively bringing the sample into contact with the solid phase antibody. A variety 
of detection methods is available, reviewed by Purchades [9], and flow injection 
immunoassays can be performed in pre-incubation or on-line format [10-13]. 
Such immunoassays have shown significant advantages, and this technique has 
now been used in clinical analysis, pharmaceutical analysis and environmental 
analysis [14-18]. 
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In a solid phase system the antibody is bound to a suitable solid matrix, such as a 
paper disk, the wall of a plastic test tube, small glass or plastic beads, Sephadex 
particles, affinity absorbent gels, etc. An antigen bound to an antibody therefore 
can be separated from un-reacted antigen simply by rinsing or centrifuging and 
washing. In addition to the simplicity of the separation it is possible to eliminate the 
background signals from samples such as blood serum. Solid phases in 
fluorescence immunoassays have been reviewed by Soini and Hemmil1i [19]. In 
flow injection immunoassay systems, Protein A, Protein G or thiophilic gel are 
normally chosen as solid phase reactors: they will be described in a separate section 
(section 1.4). 
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Fig. 1.3.1 A example of PIA signal. The first peak is unbound peak, the second 
peak is the fraction eluted from the solid phase reactor . 
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Fig. 1.3.2. A signal of FIA recorded. 
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1.4 Chromatography 
1.4.1 Affinity Chromatography 
Affinity chromatography is a type of adsorption chromatography in which the 
molecule to be purified is specifically and reversibly adsorbed by a complementary 
binding ligand immobilised onto an insoluble support matrix. The immobilised 
ligand retains its specific binding affinity. for the substance of interest and it is 
available for selective desorption of the bound substances. After washing away the 
non-interacting material, the desired molecule is eluted by adjusting the elution 
conditions, e.g. by using lower pH level or changing the ionic strength. In flow 
injection heterogeneous immunoassays, affinity chromatography is used in the form 
of a solid phase reactor to separate antibody-analyte complexes from unbound 
analyte. Immobilised protein A and protein G are commonly used in the affinity 
chromatography of antibodies. 
1.4.2 Protein A (SpA) / Protein G 
Staphylococcal Protein A (SpA) is a bacterial protein which is produced by 
Staphylococcus aureus (S. aureus) [1-3]. Protein A was first described as a 
protein antigen present in type A staphylococci by Verwey [4] but the study and 
characterisation of protein A only began in the 1960's. The 42,000 Dalton 
molecule of protein A specifically binds to the Fc region of immunoglobulin. 
Protein A binds to all the main antibodies that the clinical scientist is likely to 
generate in the laboratory but it has different binding affinity to a variety of 
antibodies sources [5-6], e.g. it binds IgG from human, goat, rabbit and pig with 
high affinity, binds horse and cow IgG with lower affinity and binds to rat IgG only 
very weakly (table 1.4.1). When in a complex with protein A, the IgG antigen 
recognition and binding is not affected, which makes protein A a very useful 
42 
· Chapter 1. Introduction 
immunological tool [7], e.g. in antibody purification or as an amplification step in 
radioimmunoassays or ELISA systems. 
Table. 1.4.1 Binding specificity of protein A to different animal species 
immunoglobulin. 
Species of polyclonal IgG Protein A binding 
Human S 
Mouse S 
Rabbit S 
Guinea pig S 
Pig S 
Dog S 
Goat W 
Sheep W 
Cow W 
Horse W 
Rat W 
Chicken nB 
note: S-strong binding, W-weak binding, nB-no binding. 
The gene for protein A has been cloned and sequenced: it encodes a protein 
consisting of five homologous IgG-binding domains [1], each one containing very 
similar sequences of about 50 amino acids and termed E, D, A, B, and C, followed 
by a C-terminal region, X which anchors the protein to the cell wall of S. aureus. 
The binding of IgO to protein A on the surface of S. aureus is associated with a 
reduction in the phagocytosis of the organism, because this is affected by the Fc-
mediated interactions of the phagocytes, thus debilitating the host's antibiotic 
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defences [8]. A schematic diagram of the structure of protein A is shown in 
Fig. 1.4.1: 
Fig.l.4.1 Schematic diagram of the structure of protein A. E, D, A, B, C, are the 
five of antibody Fc binding domains, X is the cell wall associated region and M is 
the membrane anchor region, the" Y " is represent the Fc binding sites. 
Protein A has been coupled to a wide variety of solid or gel matrices such as 
Sepharose, etc. and as a ligand binder it has been applied in immunoassays in three 
major ways [9]: 
• An immobilised immunoadsorbent, 
• An immunoadsorbent in solution, 
• A labelled binder. 
In flow injection analysis, protein A is normally used as an immobilised 
immunoadsorbent (solid phase reactor) e.g. in a immunoassay for theophylline 
[10]. Protein A binds antibody in one buffer environment, at neutral pH (pBS 
buffer pH 7.4); and antibody is dissociated from in acid pH (e.g. citric acid buffer 
I 
pH 2.5). 
However, protein A can be replaced by protein G and the complementary nature of 
their binding properties can be exploited [11]. 
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1.4.3 Thiophilic Adsorbent Gel (T-Gel) 
Most of the flow il1iection immunoassays developed to date have used protein A as 
the solid phase absorbent for binding and isolation of antibodies, but as described 
above, the essential pH change limits many of the potential fluorescence dyes that 
can be used. Thus it is difficult to utilise a pH dependent fluorophore, e.g. 
fluorescein (FITC). As a result, a new generation of solid phase absorbents has 
been developed. Thiophilic adsorption gels bind antibodies and subsequently 
release them under the mild conditions, without requiring a pH change. 
1.4.3.1 Principles and Activities of Thiophilic Adsorption Gel (T-gel! 
Thiophilic adsorption gel (T-gel) is the ~-mercaptoethanol derivative of 
divinylsulfone-activated agarose. The method of synthesis was first described by 
Porath[12]. Generally the polymer matrix (6% agarose gel in the form of spherical 
beads) is activated [13] with divinylsulfone (DVS) (which is a versatile reagent for 
coupling ligands of affinity chromatography [14] and for cross-linking agarose[15]) 
to couple mercaptoethanol. The general structure of the :r -gel can be shown 
, 
below (Fig. 1.4.2): 
A. t-OIl + (CH,,cm,SO, 
B. Agarose(P)-O-CH,-CH2-SH2-CH2=CH2 + H-S-CH2-CH2-OH ~ 
agarose(P)-O-CH2-CH2-S02-CH 2-CH2-S-CH2-CH2-0H 
C. Agarose(P)-O-CH2-CH2-S02-CH2-CH2-S-R 
Fig.1.4.2 (A.) Starting materials. (B.) The T-gel preparation. (C.) Principal 
structure of T -gel. P is the polymer matrix and R is a small aliphatic residue. 
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To study the mechanism of thiophilic interaction, Porath and Belew in 1987[16], 
used the proteolytic fragments Fab and Fc of IgG as model solutes, and found that 
there was no Fab binding to the T-gel, but the Fc fragment was retarded due to a 
weak interaction, Single amino acids were not able to bind to T -gel even at high 
salt concentrations but some dipeptides composed entirely of aromatic amino acids 
were, in the order:(trp)2» (phe)2 > (tyr)2. These results suggested that the intact 
tertiary structure of IgG is a requirement for strong binding to the T -gel. Possible 
mechanisms for the binding are shown in Fig. 1.4.3 [17], though the principles are 
still not very clear. It was suggested [12] that the sulphur in the form of a 
thioether and the adjacent sulphone group act co-operatively to bind specific types 
of proteins, in particular the immunoglobulins. So this type of interaction was 
named 'Thiophilic'. 
A thiophilic gel, like other hydrophobic matrices, binds proteins at high 
concentrations of a lyotropic salt, and releases them at lower concentrations. All 
serum proteins can be bound at high ionic strength (i.e. > 1.5 M ammonium 
sulfate) and could be specifically eluted by a decreasing ionic strength gradient. 
Using lower ionic strength starting conditions the binding becomes selective; at 0.7 
M ammonium sulfate practically no proteins bind except for IgG [18]. The 
selectivity in adsorption with respect to immunoglobulin classes and subclasses has 
not been studied but some preliminary experimental data suggest that the 'class 
spectrum' is broader than protein A. 
In 1986, Hutchens and Porath[19] studied human serum immunoglobulins and 
analysed the optimised conditions for their absorption and purification. The 
adsorption capacity was affected by ionic strength, different lyotropic salts, flow 
rate, pH, and temperature, and it was suggest that the optimal conditions for the 
binding of IgG to T -gel are: 
• An ionic strength of 0.5 M, 
• potassium sulfate is the first salt to be chosen, (Table.1.4.2), 
• the possible pH range is from 3·9, but the best pH for both adsorption and 
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desorption is pH 7.5-8.0. 
• the absorption capacity is affected at the elevated flow rates. 
• the absorption and desorption are at most the same at 4°e and 20oe. 
10 1 
1+ _ 
ag"os.-cH2,cH2·i·<i:H2-CH2-~-cH2-cH2-oH 
~7Q~\ ~ 
empty 3d orbitals ____ -~----------P-'-O,-.,-O-
electron acceptor 
Ligand Binding Site 
Protein 
electron acceptor 
Fig. 1.4.3 Hypothetical mechanism of thiophilic ligate interaction with the T -gel 
ligand involving (above), an electron-donor/acceptor or (below) a proton transfer 
process. 
Table 1.4.2 A comparison of salts in the thiophiIic adsorption of immunoglobulin 
(0.5 M salts in 20mM HEPES (pH 7.5) at 200 e). 
Salt 
(NH4)zS04 
MgS04 
KZS04 
NaZS04 
Bound % 
74.1 
78.5 
83.5 
92.5 
47 
Recovery % 
91.2 
91.0 
87.9 
83.2 
i . I ! I 
, ! 
i I I J 
I I 
i/ 
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There are some comparisons of thiophiJic gels and protein A are shown in Table 
1.4.3: 
Table 1.4.3 . 
Thiophilic adsorption gel Protein A 
species chemical syntbetic biological 
mechanism intact tertiary of IgG Fc oflgG 
absorption desorption salt dependent pH dependent 
cost cheaper expensive 
1.4.3.2 Applications of Thiophlic Adsorption Gel 
Since T -gels bind immunoglobulins from most species, and can be used without a 
change of pH, their application in a range of heterogeneous immunoassays of 
interest. Palmer et al., reported using T-gel as an alternative solid phase to protein 
A in flow injection immunoassays [20-21]. 
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1.5 Therapeutic Drug Monitoring (TDM) 
1.5.1 The Concept of Therapeutic Drug Monitoring 
In clinical practice, the questions nonnally asked about serum drug concentrations 
are the following: 
• is the patient taking the drug and how many drugs is the patient taking? 
• is the patient getting enough or too much drug? 
• is dose adjustment needed, and 
• is the drug causing any symptoms? 
Therapeutic drug monitoring (TDM) could thus be described as the study of 
individual drug serum concentration-effect relationships usually via the routine 
measurement of therapeutic drugs in blood (plasma or serum) or other biological 
fluids as an aid to improving drug therapy [1-3J. There is a therapeutic index 
which is the ratio between the average minimum effective doses and the average 
maximum tolerated doses in a group of subjects [4 J: 
Maximum non - toxic dose Therapeutic Index = 
Minimum effective dose 
1.5.2 Why Monitor Drugs and Therapeutic Range 
Any drug has a therapeutic dosage and a toxic concentration-side effect dosage. 
Some drugs have a reasonably wide difference between the therapeutic and toxic 
concentration ranges and have no serious side-effects. If the desired effect of 
therapy can easily be monitored by simple observations or clinical measurements, 
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e.g. monitoring a patient's ECG following some cardiac disease therapy, or 
eradication of infection and fever associated with it following antibiotic treatment, 
it is not necessary to measure a drug level in serum routinely, because it is 
expensive and time consuming. But in some cases, such as the treatment of cancer 
or of some endocrine diseases, the drugs have narrow therapeutic indices, e.g. 
therapeutic doses are close to toxic doses or they show considerable inter-
individual variation in plasma levels from the same doses [5], e.g. phenytoin. In 
such cases it is difficult to establish a common dose regimen for all patients, so that 
direct measurement of the plasma concentration allows the clinician to make 
appropriate changes in dosage in an individual patient, therefore a plasma level 
within the therapeutic concentration range is requested. Therapeutic ranges for 
some routinely monitored drugs are shown in below (Table 1.5.1): 
Table 1.5.1. Plasma half-life and therapeutic concentration range for some 
commonly monitored drugs. 
Drug Therapeutic range Half-life / h 
Carbamazepine 17-42 llmollJ 15 
Digoxin 1-2.3 nmolll 36 
Gentamicin 9-27 llmol/l 4 
Lithium 0.3-1.3 mmolll 22 
Methotrexate <1 llmo! 11 12 
Phenobarbitone 65-130 llmol/ 1 96 
Phenytoin 40-80 llmol/l 24 
Procainamide 17-37 llmol/l 3 
Theophylline 55-110 llmolll 8 
Insulin 1-2 mg/24 hrs 
Hydrocortisone 20 mgJ24 hrs 8-12 
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1.5.3 Analytical Techniques/or TDM 
The most commonly used bio-fluid for TDM is plasma or serum, though other 
fluids (urine, bile, sweat, saliva, cerebrospinal fluid) are utilised much less 
frequently, because they are either difficult to handle or are not able to represent 
the true drug concentration in the body [6-8]. 
Often, TDM results are required urgently, so that an analytical technique should be 
simple, quick and reliable. It must be specific for the drug request and without 
interference from structurally related compounds. 
A number of analytical techniques are currently used in TDM include 
immunoassays and chromatography. No single technique can be used for a reliable 
measurement of all drugs, but immunoassays (especially the competitive assays) 
have advantages in terms of speed and simplicity, and they are amenable to 
automation and to multi-analyte analysis, permitting much higher sample 
throughput. Inununoassays have been widely exploited in the development of free 
hormone and drug assays. 
1.5.4 Theophylline 
Theophylline, 1,3-dimethylxanthine is a methylated xanthine derivatives (others are 
caffeine and theobromine). 
Its molecular weight is 180.17, molecular formula C7H,N40 2• and chemical 
composition C 46.66%, H 4.48%, N 31.10%,017.76%: 
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The physical and chemical characters of theophylline are: a white odourless 
anhydrous crystalline powder with a bitter taste, soluble at 25°C, one part dissolves 
in 120 parts of water, or 1 in 80 of alcohol or 1 in 200 of chloroform, soluble in 
ether and in dilute acids and alkali hydroxide solutions. DV absorption maximum 
at 274 nm[9]. 
Therapeutic uses and toxicity: It is still not clear how theophylline exerts its effects, 
perhaps the mechanism is inhibition of phosphodiesterase by theophylline resulting 
in an intracellular accumulation of cAMP (adenosine 3'5'-cyclic monophosphate) 
and a subsequent relaxation of bronchial smooth muscle. The methyIxanthines 
relax various smooth muscles, notably bronchial muscle (especially if the bronchi 
have been constricted either experimentally by a spasmogen or clinically in 
asthma), excite the central nervous system (CNS) and stimulate cardiac activating. 
Theophylline is more effective than caffeine and theobromine, produces a definite 
increase in vital capacity, and therefore is of value in the treatment of bronchial 
asthma, apnoea and obstructive lung diseases. An oral dosage of 400-3200 
mg/daily of theophylline is equivalent to a plasma level of 10-20 mg/l. If plasma 
concentrations are <10 mg/l, most patients show little benefit from the drug; if they 
are >20 mg/l, there is a high incidence of toxicity to gastric secretion, smooth and 
skeletal muscle, the cardiovascular system and the central nervous system, 
appearing nausea, vomiting, headache, or in extreme cases, convulsions and death 
[10-12]. 
Current methods for measuring theophylline in serum include radio-, enzyme and 
fluorescent immunoassays, spectrophotometer, TLC, GLC and HPLC [13-16]. 
1.5.5 Hydrocortisone 
Hydrocortisone (cortisol) is a corticosteroid hormone, a derivative of cortisone, 
produced and secreted by the adrenal glands. In humans, hydrocortisone is the 
main carbohydrate-regulating steroid, and aldosterone is the main electrolyte-
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regulating steroid, therefore, the actions of hydrocortisone extend to almost every 
cell in the body. 
Hydrocortisone, 11,17,21-Trihydroxypregn-4-ene-3,20-dione, its molecular weight 
is 362.47, molecular formula C21H300, and chemical composition C 69.59%, H 
8.34%, 0 22.07%, hydrocortisone is a white odourless anhydrous crystalline 
powder with a bitter taste, insoluble in water at 25°C and UV absorption maximum 
at 242 nm [9-10, 121, the structure of hydrocortisone is shown below: 
Therapeutic uses and toxicity: The pharmacological actions of hydrocortisone are 
highly complex as adrenal corticosteroids affect almost every organ in the body. 
Effects include: (1) carbohydrate, protein and fat metabolism, because it increases 
blood glucose and liver glycogen levels by stimulating gluconeogenesis, this bring 
on a resulting in a negative nitrogen balance. (2) electrolyte and water metabolism: 
hydrocortisone increases the rate of sodium absorption and potassium excretion 
several fold, this will occur physiologically in response to sodium or volume 
depletion or both. (3) hydrocortisone directly stimulates cardiac output and 
potential the responses of vascular smooth muscle to the pressor effects of 
catecholamines and other vasoconstrictor agents. Thus hydrocortisone plays an 
important role in the regulation of blood pressure. (4) hydrocortisone blocks all 
steps of the inflammatory process, i.e. it inhibits the influx of polymorphonuclear 
leukocytes, eosinophils, basophils, mononuclear cells and Iymphocytes into tissues, 
resulting in a diminution in heat, erythema, swelling and tenderness. However, it 
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does not suppress antibody production. Therefore hydrocortisone is widely used 
to treat any kind of inflammation and allergic conditions especially in emergencies. 
The rate of secretion of hydrocortisone by the adrenal cortex of a normal human 
subject under optimal conditions is about 20-30 mg/day. Concentrations in 
peripheral plasma are relatively high in the early morning hours (16 flg/dl), but 
decline during the day and reach a minimum during the evening (4 flg/dl). 
Hydrocortisone absorption and excretion are by liver, secretion is dependent on the 
concentration in the circulation system and controlled by the pituitary 
adrenocorticotropic hormone (ACTH). Hydrocortisone administered in many 
forms, general the oral dose is 40-60 mg/daily. High dose or long term treatment 
with hydrocortisone may cause serious disorders [15], these include: 1) a 
heightened susceptibility to serious bacterial, viral and fungal infections, thus it 
makes more difficult to antibiotics administrations with steroids. 2) peptic ulcers 
on gastric mucosa. 3) the hyperglycemic action effects decrease glucose tolerance 
and responsiveness to insulin. 4) osteoporosis is a conunon side effect in older 
patients. 5) fluid and electrolyte disturbances: these are increases in potassium 
excretion, which cause muscle weakness. sodium and water retention, which cause 
hypertension. 6) acne. striae, truncal obesity, deposition of fat in the cheeks, upper 
part of the back, etc. 
Radioinununoasay is still applied to the determination of hydrocortisone 
concentrations in biological fluids [17], but different non-isotopic inununoassays 
were developed from 70s', using fluorescent [18-22], enzymatic [23]. and 
chemiluminescent [24-25] labels. 
1.5.6 Insulin 
Insulin is a simple protein hormone produced and secreted by the B-cells of the 
islets of Langerhans within the pancreas of all vertebrates. In its monomeric or 
active form, the molecular weight of insulin is about 6,000 and it consists of 51 
amino acids arranged as two polypeptide chains, A chain and B chain connected by 
55 
Chapter 1. Introduction 
disulfide bonds. Destruction of the disulfide linkages reduces biological activity. 
The amino acid sequence and composition of animal insulins, e.g. bovine, pork, 
may differ from human insulin, but their biological and immunological actions are 
similar. The biochemical actions of insulin are complex: it regulates carbohydrate 
metabolism, influences the synthesis of proteins and the formation and storage of 
neutral lipids. Insulin directly secretes into the bloodstream has the effect of 
reducing the blood levels of glucose: following a meal rich in carbohydrates, the 
blood levels of insulin can increase several fold. The rate of secretion of insulin in 
normal human is between 18-40 units/day or about 0.2-0.5 unitslkg of body weight 
per day or 1-2 mg124 hrs. If insulin is absent, is called diabetes mellitus, the high 
levels of blood glucose. Insulin is recommended for the treatment of insulin-
dependent diabetes mellitus (IDDM) (type I diabetes) and diabetic comas. 
Administration is by injection, the various formulations of insulin being generally 
classified as short-acting (0.5-14 hr), intermediate-action (1-28 hr), and long-action 
(4-36 hrs) [10, 12]. 
1.5.7 AZhumin(s) 
Albumins are a group of proteins characterised by heat coagulation ability and 
solubility in water. The molecular weight of albumin is 66,00-68,000. They are 
found in nearly all living body tissues: 50-60% of plasma proteins is albumin, with 
concentrations of 4-6 g/lOO ml. Albumin is widely utilised in biochemistry, 
pharmaceutics, medicine, and food science fields 
1.5.8 Transferrin( s) 
Transferrins are a group of homologous non-heme, iron-binding glycoproteins. 
The molecular weight is 76,000-81,000, they present in a variety of physiological 
fluids especially in serum and cells in most vertebrate animals, in egg whites and in 
I 
mammalian milk, tears and leukocytes. Their biochemical function is principally 
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iron transport to developing red blood cells for haemoglobin synthesis. Each 
molecule is able to bind two Fe3+ ions to form a salmon-pink complex. The serum 
concentration oftransferrin is about 2-3% of the plasma proteins [27-28]. 
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2.1 Instruments and Materials 
2.1.1 Reagents 
SUBSTANCE 
Proteins and Drugs 
Bovine serum albumin (BSA) (sheep) 95% mw 68,000 
Hydrocortisone-21-hemisuccinate C2,H3.O, mw 462.5 
Insulin (Bovine pancreas) 0.5 mg/ml mw 6,000 
Theophylline C7H.N.02 mw 180.2 
Theophylline-8-fluorescein tracer Iml 
Transferrin (human) 95% mw 80,000 
Wellferon 3.39mg/ml mw 2,000 
Antisera 
BSA antiserum (sheep) 42 mg / ml 
Hydrocortisone-21-hemisuccinate (sheep) antiserum 
O.5mg/ml 
Insulin antiserum (mouse) monoclonal 1.0 mg/m! 
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Transferrin antiserum (anti-human) (goat) 21.5 mg I m! 
TheophyUine-8 antiserum (sheep) O.4mg/m! 
Wellferon antiserum (bovine) 21.5 mg/m! 
Fluorescent Labels 
Cascade Blue acetyl azide trisodium salt 68% (c2284) 
C\8H,N30nS3Na3 mw 607.42 
Fluorescein isothiocyanate isomer 1 (FITC) 
C21HnNOsS mw 389.38 
Tetramethylrhodamine isothiocyanate isomer R (TRlTC) 
C2sH2IN303S mw 443.5 
Buffer Reagents 
Sodium hydrogen carbonate NaHCO, mw 84.01 
Sodium carbonate Na2COJ mw 105.99 
Sodium chloride NaCl mw 58.4 
Potassium dihydrogen phosphate KH2PO. mw 136.09 
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Disodium hydrogen phosphate Na,HPO, mw 141.96 Fisons 
Potassium sulfate K,SO, mw 174.27 Fisons 
Sodium dihydrogen phosphate NaH,PO,.H,O mw 156.01 Fisons 
Sodium azide NaN3 mw 65 Sigma 
Other Reagents 
l-Ethyl-3-(3-dimethlyaminopropyl) carbodiimide) Sigma 
I 
hydrochloride (EDAC) C,Hl7N3.HCI row 191.7 
N-Hydroxysuccinimide (NHS) C,H,N03 row 115.09 Sigma 
~-Mercaptoethanol C,H,OS mw 78.13 Sigma· 
Hydroxylamine.HCI HO.NH,Cl row 69.49 
N,N-dimethylformamid (DMF) C3H,NO row 73.1 Fluka 
Methanol CH40 mw 32.04 Fisons 
Agarose Sigroa 
CHAPS C32HSSN20,S row 614.9 Sigma 
All chemicals were analytical grade. 
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2.1.2 Chromatographic Columns 
PD 10 column 10 ml 
Glass column 0.35 x 2.0 cm 
Glass column 0.6 x 10.0 cm 
2.1.3 Column Matrix 
Sephadex gel G-15, G-25 
Thiophilic absorbent gel (T -gel) 
wet bead id = 45-165 !lm 
Protein A-pore 
2.1.4 Cell 
25!l1 quartz flow cell 
Icm quartz fluorescence cell 
Icm quartz UV cell 
2.1.5 Flow Injection Equipment 
Gilson Minipuls 2, peristaltic pump 
Gilson Minipuls 3 peristaltic pump 
Polyethylene 25 micron frit 
Poron Teflon 10, 40, 70, 100 micron frits 
Transmission tubing 0.8 mm id. 
Standard pump tubing 1.65 mm id. 
Injection and switch valves 
Plastic I ml syringe 
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Pharmacia 
Omnifit 
Omnifit 
Sigma 
Pierce & Warriner 
Per Septive Biosystems 
Hellma 
Hellma 
Hellma 
GilsonLtd 
Gilson Ltd 
Omnifit 
Omnifit 
Altec 
Altec 
Omnifit 
Becton Dickinson 
Chapter 2. Instrumentation and Materials 
2.1.6 Pipette 
Automatic pipettes Vo!. 0.5-10J.ll, 5-40J.!1, 40-200J.!1, 1000J.ll Gilson Ltd. 
2.1. 7 Instrumentation 
Perkin Elmer LS-50B Spectrometer 
Model Fl 4500 Spectrometer 
Pye Unicam 8700 UV/visible Spectrometer 
Perkin Elmer 
Hitachi 
Pye Unicam 
2.1.8 Supplier and Address 
Altec 
Amersham Life Science, Inc. 
Becton Dickinson 
Fluka Chemicals Ltd. 
Fisons Scientific Equipment 
Gilson Medical Electronics Ltd 
Glaxo-Well come 
Hitachi 
Hellma 
lGi Ltd (Immunogen International) 
Molecular Probes 
Omnifit 
Pharmacia 
Pierce & Warriner Ltd 
PyeUnicam 
Perkin Elmer 
Per Septive Biosystems Ltd. 
Sigma Chemical Co. 
Alton Hampshire UK. 
Arlington Heights US. 
Dublin Ireland 
Gillingham, Dorset UK. 
Loughborough UK. 
France 
Beckenham, Kent UK. 
Instrument Division Hitachi Ltd. Tokyo 
Japan 
Germany 
Gateshead UK. 
Cambridge UK. 
Cambridge UK. 
Milton Keys UK. 
ChesterUK. 
Cambridge UK. 
Beaconsfield, Buckinghamshire UK. 
Hertford, UK. 
Poole, Dorset. UK. 
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2.2 Experiments 
2.2.1 Buffers 
Carbonate Buffer (1) pH 9.4: 
Sodium hydrogen carbonate NaHC03 2.9g I L (0.0345 Mol) 
Sodium carbonate Na2C03 1.59g I L (0.015 Mol) 
Carbonate Buffer (2) pH 10: 
Sodium hydrogen carbonate NaHC03 5.8g I L (0.069 Mol) 
Sodium carbonate Na2C03 3.18g I L (0.030 Mol) 
Phosphate Buffer saline(PBS) pH 7.4: 
Sodium chloride NaCl 8.0g I L (0.137 Mol) 
Potassium dihydrogen phosphate KH2P04 0.2g I L (0.00147 Mol) 
Disodimn hydrogen phosphate NaH2P04 2.9g I L (0.020 Mol) 
, 
Binding Buffer(BB) pH 8.0: 
Potassium sulphate K2S04 87.l4g IL (0.5 Mol) 
Disodium hydrogen phosphate NaHP04 13.41g I L (0.095 Mol) 
Sodium dihydrogen phosphate NaHzP04.HzO 7.8g I L (0.050 Mol) 
Elution Buffer(EB) pH 8.0: 
Disodium hydrogen phosphate NaZHP04 13.41g I L (0.095 Mol) 
Sodium dihydrogen phosphate NaH2P04.H20 7.8g I L (0.050 Mol) 
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The following solutions were purchased from the laboratory of the department: 
Tris-tricine lactate Buffer pH 8.6: 
Tris 13.2 g 
Tricine 6.2 g 
Calcium lactate 2.0 g 
Sodium chloride 4.5 g 
Deionised water 2000 ml 
Destaining Solution: 
Ethanol: Aceticacid: water = 5:2:9 
Coomassie Brilliant Blue Stain: 
5g of stain was dissolved in 450 ml of 96% ethanol, 100 ml of acetic acid and 450 
ml of water. 
All buffers were adjusted with the use of 5M NaOH, 1M HC1, 0.1 % w/v of NaNJ 
was added and then the buffers stored at 4°C. 
2.2.2 pH Measurement 
pH measurements were carried out using a Philips PW9420 pH meter(UK.). The 
instrument was calibrated with standard buffer solutions at pH 7.00 and lO.OO ± 
0.01, every time before use. 
2.2.3 Water Purification 
Solutions were prepared using deionised water (HPLC quality) which purified by 
the ultra pure water system (Elga Ltd. UK.). 
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2.2.4 Mass Detennination 
Weighing operations were made using a electronic five place balance Precise 
405M-200A (Switzerland). 
2.2.5 Pipetting 
Pipetting was carried using Gilson Pipetman (France) variable volume automatic 
pipettes throughout the project. 
2.2.6 Fluorescence Measurement 
Fluorescence spectra and intensity were record at room temperature using Perkin-
Elmer LS-50B and Hitachi FI 4500 luminescence spectrometers. The schematic 
diagram for the LS-50B is shown in Fig. 2.1 and Table 2.1, and for the FI-4500 
spectrometers is shown in Fig. 2.2 and Table 2.2. The LS-50B and Hitachi FJ-
4500 spectrometers were also used as a detector in the flow injection experiments 
respectively. The LS-50B was interfaced with an Epson AX3 personal computer, 
and the FI 4500 spectrometer was interfaced with a ROCK personal computer for 
data manipulation and processing. 
2.2.7 Absorbance Measurement 
Absorbance measurements were carried out on the PhiJips Pye-Vnicam PV8600 
VV / Visible single beam spectrophotometer. The diluent buffers were used as the 
reference. 
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2.2.8 Column Packing 
2.2.8.1 Packinjt, of Gel Filtration 
Sephadex gel G-25 was swollen in 0.9 % NaCI of dry gel 4-6 ml/g of swelling 
factor overnight. A PD-l 0 column was filled with 10 ml of pre-swollen Sephadex 
gel G-25 using pasteur pipette and then PBS buffer was pumped through to 
compact the column to wash out the salt. 
2.2.8.2 Packing Solid Phase Immunoreactor 
Thiophilic gels (pre-swollen by the manufacture) were carefully pipetted into a 
glass column using a pasteur pipette to avoid air bobbles. 
3.5 mm id.x 20 mm I of column was filled approximately 0.2 ml ofT-gel. 
10 mm id. x 60 nun I (gel length 2-3 mm) of column was filled approximately 0.3 
ml ofT-gel. 
The T -gel columns were equilibrated with binding buffer and stored at 4°C after 
use. 
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Table 2.1 The parameters of LS-50B spectrometer: 
Variable Limits for Typed Commands Increment 
Min Max 
EX Monochromator 200nm 800nm 1 nm 
EM Monochromator 200nm 900nm Inm 
Ex Slit Width (recommended 2.5 x 10nm 15 x 10nm 0.1 x 10nm 
values: 2.5,5, 10, 15 nm) 
EM Slit Width (recommended 2.5 x lOnm 20 x lOnm 0.1 x lOnm 
values: 2.5, 5, 10,20 nm) 
Gate Time 0.01 ms 500ms 0.01 ms 
Delay Time Oms 9490ms 0.01 ms 
Cycle Time 20ms 9999 ms 1 ms 
Flash Count 1 10 1 
PM Voltage 600 V 900 V IV 
Scan Speed 10nm/min 1500nmlmin Inm1min 
Response 0.02 x 10 s 9.99 x 10 s 0.01 s 
I 
No. of Scans 1 999 1 
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Table 2.1 The parameters of Fl4500 Hitachi spectrometer: 
Sensitivity 
Minimum sample volume 
Photometric system 
Light source 
Monochromator 
Wavelength range 
Slit width 
Resolution 
Wavelength accuracy 
Wavelength scan speed 
Response 
Photometric value display 
range 
Power consumption 
Dimensions 
Weight 
SIN 100 or higher for Raman spectrum of water at 
EX wavelength 350 nm, slit width 5 nm 
0.6mJ 
Monochromatic light monitoring ratio calculation 
150WXelamp 
Aberration-corrected concave diffraction grating: 
900llmm 
200-730 nm and 0 nm 
EX: 1.0,2.5,5.0, 10 nm 
EM: l.0, 2.5, 5.0, 10, 20 nm 
1.0nm 
Within±2nm 
15-30000 nrnImin 
o to 98%, 0.004, 0.01, 0.05, 0.1, 0.5, 2.0, 8.0s 
0.000-9999 
100, 115,220,230,240 VAC, 50/60 Hz, 400 VA 
680w x 660d x 340h mm 
58 kg 
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Fig. 2.1 The optical diagram of LS-50B spectrorneter. 
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Fig. 2.2 The optical diagram of F14500 Hitachi spectrometer. 
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3.1 Synthesis, Purification and Determination of Conjugates 
3.1.1 Synthesis of Conjugates 
Proteins including serum antibodies can be labelled by chemical combination with 
fluorescent dyes, without material effect on the proteins. Coons [1-2] reported 
proteins which were labelled with FITC in 1950's. Fluorescent protein conjugates 
were synthesised according to McKinley (1966) [3] and Chen (1969)[4]. 
Generally, the conjugation takes place in a buffer with slightly basic pH and for 
each kind of conjugate, the dye is required in serial molar ratios to the protein, for 
example, 2 times, 5 times, 10 times and 20 times etc. than the protein. 
The dye was dissolved in 1 rnl carbonate buffer pH 9.3, each portion of the protein 
was also dissolved in 1 rnl of the same buffer, followed by mixing of the dye and 
the protein solutions together making 2 rnl for each conjugate, then the mixture 
was stirred for 24 hours at 4°C. Cascade Blue and TRITC were protected from 
light through the whole process. The techniques for the synthesis of a fluorescent 
derivative of small molecules are much more complex and will be described in 
section 3.9. 
3.1.2 Purification of Conjugates and Detennination of Conjugation Ratios 
The method for purification of a conjugate is described by Porath etc. [4-5]. The 
resultant reaction was purified by gel filtration using a 10 rnl of PD-1O colunm 
which was filled with Sephadex gel G-25 to remove the excess non-reacted 
fluorescent dye from the mixture. The on-line purification was monitored using the 
LS-50B fluorimeter. The colunm was eluted using PBS buffer pH 7.4 with the 
first fraction being collected. The conjugate was stored at -20°C as a stock 
solution. 
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The labelling efficiency (ratio of the dye bound to protein) was determined (Table 
3.1.1) from the absorbances at the define "-1 and "-2 of maximum absorption of the 
dye and protein [6]: 
AA.l=EproteinA.l X [protein] + Edye A.J x [dye] 
AA.2 = Eprotein 1..2 x [protein] + Edye A.2 x [dye] 
A = Ecb 
A = absorbance 
E = molar absorptivity 
c = molecule in molar concentration 
b = path length in cm 
(dye] = molar concentration of protein or dye 
Table 3.1.1 Labelling efficiency for protein conjugates: 
Name of conjugate 
Cascade Blue-BSA 
FITC-transferrin 
Labelling efficiency (dye:protein) 
molar ratio 
20:1 
10:1 
20:1 
10:1 
5:1 
2:1 
labelling ratio 
1.41 
1.36 
3.77 
3.44 
1.82 
0.86 
(3-1) 
(3-2) 
The fluorescence intensities of the various conjugates were d~termined on the LS-
SOB fluorimeter after passage through the T -gel solid phase colunm, it was found 
that the conjugates of C. Blue-BSA and FITC-transferrin displayed their highest 
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fluorescence at a 10: 1 molar ratio of the dye to protein, therefore this ratio was 
used throughout the project. 
3.2 Thiophilic Absorption Gel (T·gel) Binding Experiments 
3.2.1 Ionic Strength Effects to T-gel Binding? 
T-gels were developed in 1972 [7-8] and can be used in affinity chromatography to 
develop flow injection immunoassays (chapter 4, section 1.4.4). Antibody binding 
to T -gel is dependent on the ionic strength of the buffer, the optimum being 0.5 
mol/l of potassium sulfate in a PBS buffer pH 8.0. Anti-transferrin antibodies, the 
same antibodies with FITC labelled transferrin and the antibodies with labelled and 
unlabelled transferrin were investigated to discover their suitability and binding 
capacity to the T-geL 
The data in Table 3.2.1 shows that when the ionic strength was increased by 
addition of K2S04 the antibody binding efficiency was also increased. The same 
samples were also measured at the excitation and emission wavelengths of the 
antibody. The results being shown in Table 3.2.2. 
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Table 3.2.1. Antibody binding to aT-gel column at different ionic strengths. All 
the samples were studied under the same conditions i.e. volume, concentration and 
flow rate (2 mlIrnin). The samples and conditions for the experiment were: 
sample #1) antibody only: 10 III of 1:20 anti-transferrin + 130 III ofPBS buffer, 
ex/em = 280/335 nm, slits 10/10 nm. 
sample #2) antibody with FITC labelled transferrin: 10 III of 1 :20 anti-transferrin 
+ 1:10 of conjugate 5 III + 125111 ofPBS buffer, 
ex/em = 495/525 nm, slits 10/10 nm. 
sample #3) antibody with labelled and unlabelled transferrin: 10 III of 1:20 anti-
transferrin + 1:10 of conjugate 5111 + 40 III (40 Ilglml) of transferrin + 
85 ).Il of BPS buffer, ex/em = 495/525 nm, slits 10/10 nm. 
[ionic] moJ/1 0.125 0.25 0.50 0.75 
fl int. (pk.a.) 1.6 24.7 167 341 anti-transferrin 
only (#1) 
C.V. %n=4 1.6 6.0 1.9 0.2 
fl int. (pk.a.) 1.9 7.4 11.9 29.4 antibody + 
conjugate 
C.V. %n=4 6.4 5.7 6.0 2.5 (blank) (#2) 
fl int. (pk.a.) 48 46 50 47 antibody+labelled 
and unlabelled 
BIBO upto 50% 2.8 2.4 10 6.4 transferrin 
(standard) (#3) 
C.V. %.n=4 
Note: When the concentrations of K2S04 were increased above 0.75 molll, it began 
to saturate and required constant stirring. 
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Table 3.2.2 Samples (same as Table 3.2.1) were measured at protein's 
wavelength, ex/em were 280/335 nm, slits 10/10 nm, flow rate 2.0 mlImin. 
Flint. C.V.% sample 
(pk.a.) (n=3) 
#1) 243 2.3 
#2) 250 5.2 
#3) 246 2.0 
1:20 anti-transferrin 1OIlIDOllI PBS = 140111 
1:20 anti-transferrin 1OJ!l + 1:20 transferrin-
FITe Sill +1251ll PBS =1401l1 
1 :20 anti-transferrin lOllI + 1 :20 transferrin-
FITe Sill + transferrin 40lll +S51ll PBS =140lll 
From the results shown on the Table 3.2.1 and 3.2.2, it clear that the antibody 
binding to the T -gel is not affected by the presence of transferrin and FITe labelled 
transferrin. The antibody binding to T -gel is dependent on the ionic strength of the 
binding buffer, the chosen ionic strength being 0.5 moll! of K2S04 in a PBS buffer, 
pH S.O. Moreover, the methods in Table 3.2.2 show that ther7 is little non-specific 
binding of transferrin or FITe labelled tranSferrin to the T -gel, such that the 
protein would also fluorescence at ex/em of 280/335 nm if such non-specific 
binding had occurred. 
3.2.2 Column Behaviour 
Investigation was required to discover the behaviour of analytes, antibodies, and 
fluorophores on the T -gel solid phase column under different conditions. A given 
reagent under the same conditions presents different fluorescent intensities, non-
specific binding characteristics and chromatographic behaviour on T -gel and 
Protein A. 
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3.2.2.1 Antibody Behaviour on the Column 
Anti-transferrin (severally diluted) was injected onto a T-gel column. Fig.3.2.1 
shows a signal produced by the antibody and Fig.3.2.2 shows the binding levels on 
T-gel. Ex/em = 280/335 mn, slits 10/10 nm, flow rate 4.0 mlImin, injection loop 
25 ~l. 
fl. 10.0 
[nl . 
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•• 
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, . 
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In 
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20 .0 60 80 100 120 140 160 1/10 200 220 240 260 no 300 320 3H 
'" 
Fig.3.2.1 Fluorescence profile of antibody (1: 100 anti-transferrin) on T -gel. 
Peak (l) is unbound peak, peak (2) is bound peak. J, is shown where the binding 
buffer changing to the elution buffer ( J, - this being the switch point illustrate 
throughout the thesis). 
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Fig.3.2.2 A antibody (anti-transferrin) bound to T-gel against the concentrations. 
The bars are the fluorescence intensities (pk.a.) of the antibody binding levels on 
the T-gel. 
The figures of Fig.3.2.l-3.2.2 show that antibody bound to T-gel is dependent on 
the concentration of the antibody, but the antibody binding levels are not fuJJy 
proportional to the antibody concentration. 
3.2.2.2 Analytes Behaviour on the T-gel Column 
Bovine serum albumin(BSA), human transferrin, bovine insulin and theophylline 
(200 ).lg/ml) were individually injected and passed through the T -gel column. The 
results are shown in Fig. 3.2.3. 
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Fig.3.2.3 Fluorescence profile of analytes behaviour on T -gel. The same 
concentration (200 ~glml) of BSA, transferrin, insulin, and theophylline were 
injected through T-gel column. ex/em = 280/335 nm, slits 10/10 nm, flow rate 4.0 
mlImin. (ub = unbound peak, bd = bound peak). The ratio (%) of NSB to 
unbound peak (pk.a.) are: transferrin 6/818 = 0.7 %, insulin 18.2/17.6 = 103 %. 
In Fig.3.2.3, insulin shows a highly percentage of NSB to T-gel, T-geI which 
basically made from agarose (~-mercaptoethanol derivative of divinylsulfone-
activated agarose) [9] is a widely used as chromatographic medium. To ensure 
that the NSB was caused by the thiophilIic interactions and not agarose the same 
concentrations (200 !lglml) of BSA and insulin were examined on a 1 % agarose 
filled column. Fig.3.2.4 shows that there is no NSB of BSA or insulin to agarose, 
ex 280/em 335 nm, slits 10/10 nm, flow rate 2.0 mJ/min. 
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Fig.3.2.4 The same concentrations of BSA and insulin were examined on a 1 % 
agarose filled column. 
3.2.2.3 Fluorescent Dyes Behaviour on the T-gel Column. 
Cascade Blue, Fluorescein (FITC), Rhodamine (RTlC), Cy5 and BODIPY (6117) 
was individually injected and passed through the T -gel column, the results are 
shown in Fig.3.2.5-3.2.9. 
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Fig.3.2.5 The fluorescence signal 
of 21lg/rnl Cascade Blue passed 
through the T -gel column. ex/ern = 
410/430 nrn, slits 10/10 nrn, flow 
rate 4 rnlIrnin. 
Fig.3.2.6 The fluorescence signal 
of 21lg/rnl FlTC passed through the 
T -gel colunrn. ex/ern = 495/525 
nrn, slits 10110 nrn, flow rate 4 
rnlIrnin. 
Fig.3.2.7 The fluorescence signal 
of 21lg/rnl TRITC passed through 
the T -gel column. ex/ern = 550/575 
nrn, slits 10/10 nrn, flow rate 4 
rnlIrnin. 
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Fig.3.2.8 The fluorescence signal 
of 2J,.Lglml Cy5 passed through the 
T-gel column. ex/em = 6451668 
nm, slits 10/10 nm, flow rate 4 
mlImin. 
Fig.3.2.9 The fluorescence signal 
of 2J,.Lg/ml BODIPY (6117) passed 
through the T-gel column. ex/em = 
540/570 mn, slits 10/10 nm, flow 
rate 4 mlImin. 
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From the results above it can be seen that: 
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1) the fluorescence intensities of the antibody and therefore the binding onto T -gel 
solid phase reactor is not fully proportional to antibody concentration. 
2) BSA and theophylline have no significant non-specific binding onto T-gel, 
transferrin has a small amount of non-specific binding (less than 1 % of the 
unbound). But insulin shows a great deal of NSB onto T-gel (103 % of NSB to 
unbound), the NSB peak being similar to the unbound peak. 
3) the fluorophores of Cascade Blue, FITC, RITC, CyS and BODIPY show little 
NSB onto T -gel. 
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3.3. Flow Rate 
Flow rate affects antibody-reactor binding because when the flow rate is increased 
the antibody contact time with the matrix is decreased, as a result the fluorescence 
response is smaller. One of objectives in flow injection immunoassay is to reduce 
the analysis time, so an optimised flow rate is one in which the speed of the 
analysis is maximised without significant loss of the signal. Each individual assay 
may requires a different flow rate. An example of a flow rate affects antibody 
binding shown in Table 3.3.1. 
Table 3.3.1 Flow rate against the antibody bound. Anti-serum transferrin was 
diluted to 1:40 with binding buffer. ex/em = 280/335 nm, slits 10/10 nm. 
flow rate unbound bound C.V. % n=4 ratio of bound % 
mlImin (fl. into pk.a.) (fl. int. pk.a.) (bound peak) (boundlunbound) 
6.0 1210 366 6.7 30 
5.0 1583 529 4.7 33 
4.0 1686 620 3.8 37 
3.0 1820 749 4.0 41 
2.0 1900 813 3.0 43 
1.0 2930 1533 2.0 52 
, 
0.5 3608 2800 2.5 78 
The results show that both of the antibody bound and unbound peak areas are 
decreased while the flow is increasing, the reasons being: 
1) when the flow rate is increased the antibody contact time with the matrix is 
decreased. 
2) at same time the sample time in the flow cell is decreased. Therefore when the 
flow rate is increased the antibody bound ratio is decreased, i.e. as at 6.0 mlImin 
the bound ratio of bound peak is 30% but at 0.5 mlImin is 78%. 
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It was also found that the quality and size of the frits in the reactor also affected 
the flow rate (Fig.3.3.1). 25 micron polyethylene frit was found to provide the best 
flow characteristics so it was used throughout the project. 
flow 4.5 
rate 
----
25 micron poly ethylene 
ml/min 
4 
----
10 micron teflon 
3.5 
--0-- 40 micron teflon 
3 --a- 70 micron teflon 
--A- 100 micron teflon 
2.5 
2 
J.5 
o 2 3 4 , 
time (hrs) 
Fig.3.3.1 The effect of frit type on flow rate. Various frits were tested on the 
T-gel column while a continual stream (4.0 mlImin) of binding buffer was passed 
through the column. 
3.4. Ratio of Conjugate to Antibody 
An optimised concentration ratio of the conjugate and the antibody is required for 
each individual assay. The method used for an example of FITC labelled 
transferrin assay was: 
1) with the concentration of FITC-transferrin constant (e.g. 1:10 diluted = 
0.67mg/ml labelled transferrin in the conjugate). add decreasing amounts of the 
antibody (e.g. from 1:10 to 1:100 = 2.15-0.215 mg/ml). then 
2) with the antibody dilution constant (e.g. 1: 10). add various amounts of FITC-
transferrin (e.g. 1:10-1:100", labelled transferrin 0.67-0.067 mg/ml). 
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The results are shown in Table 3.4.1. From these results it can be seen that the 
optimum concentrations and volume for the assay are: 
{
1:60 FITC- transferrin 100)!1 
1 :80 anti - transferrin 100)!1 
These volume and concentrations would give the best response for T -gel bound 
fraction and lower concentration of it was required for their immunoassay. 
Table 3.4.1 Fluorescence intensities (bound peak) at different conjugate to 
antibody concentrations. The sample contained 1: 10-1: 100 FITC-transferrin, 1: 10-
1:100 anti-transferrin, ex/em:; 495/525 nm, slits 10110 nm, flow rate 4.0 mlIrnin. 
conjugate antibody diluted 
diluted 1:10 1:20 1:40 1:60 1:80 1:100 
fluorescence intensity (antibody bound pk.a.) 
1:10 160 158 150 110 90 70 
1:20 140 136 128 88 90 60 
1:40 120 118 100 70 80 48 
1:60 80 78 70 54 46 38 
1:80 60 56 50 48 40 30 
1:100 48 42 40 36 30 26 
3.5. Pre-incubation 
The pre-incubation method involved the mixing a known amount of labelled 
analyte and a given amount of unlabelled analyte with a known amount of 
antibody, the labelled and unlabelled analyte molecules competing for the limited 
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amount of antibody binding sites. The mixture was incubated at room temperature 
before loading onto the flow injection system [10]. 
3.6 Single Immunoassay for Albumin (BSA) 
For the albumin (BSA) immunoassay, BSA was labelled with Cascade Blue. 
Previous results had shown that BSA and Cascade Blue showed very little NSB on 
T-gel (chapter 3, 3.2) and the conjugate of C. Blue-BSA also no NSB (Fig.3.6.1). 
The excitation and emission wavelengths of Cascade Blue are 410 and 430 nm and 
an effecting unchanged after conjugation to BSA (Fig.3.6.2). 
The sample was pre-incubated for 5 minutes, then loaded into a 25111 injection loop 
and injected onto the T -gel column in binding buffer. When the first fluorescence 
peak had returned to the baseline, the stream was then switched to elution buffer to 
elute the bound complex until the second elution peak returned to the baseline 
again. Switching back to the binding buffer allowed re-equilibration of the column 
ready for the next sample. The flow rate was 4 m1!min and the fluorescent 
intensities were recorded by the LS-50B data manager software. 
Displacement studies were done in order to generate a calibration curve for the 
BSA immunoassay. The values of the bound peaks area were used to calculate the 
percentage displacement using the equation given below: 
% displacement = B / Bo % 
.!!.- % = Elution peak area at the stated analyte concentration x 100% (3-1) 
Bo Elution peak area at zero analyte concentration 
The results for albumin (BSA) immunoassay are shown in Table 3.6.1 and 
Fig.3.6.3. The assay was repeated three times. 
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Fig.3.6.1 Fluorescence profile of the conjugate of C.Blue-BSA through T-gel 
column. ex/em = 410/430 nrn, slits 10/10 nrn, flow rate 4 mlImin. 
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Fig.3.6.2 Excitation and emission spectra of Cascade Blue and C.Blue-BSA. 
ex/em = 410/430 nrn, slits 10/10 nrn (concentration of the samples was unknown). 
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Table 3.6.1 Single immunoassay for albumin(BSA). 
25 III of sample was taken from a pre-incubation mixture of: 
1
1:40 C. B - BSA, 100 III 
1:40 anti - BSA, 100 III 
BSA, 100 III (with binding buffer) 
then injected into the flowing system. 
[BSAlllglml 
0.0 
50.0 
100.0 
150.0 
200.0 
250.0 
300.0 
8/80 100 
% 
90 
80 
70 
60 
50 20 
fl int (pk.a.) 
56.0 
50.4 
45.0 
38.1 
35.8 
34.7 
32.5 
50 
B/Bo% 
100.0 
90.0 
80.0 
68.0 
64.0 
62.0 
58.0 
100 
C.V. % (n=4) 
1.3 
2.9 
3.9 
2.2 
2.3 
3.2 
2.8 
300 
[BSAll'g/ml 
Fig.3.6.3 Calibration curve for albumin (BSA) immunoassay. ex/em = 410/430 
nm, slits 10/10 nm, flow rate 4 ml/ min. 
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3.7 Single Immunoassay for Transferrin 
For the transferrin immunoassay, FITC was used as a label. Previous results 
(chapter 3,3.2) have shown that FlTC has no NSB, but transferrin has some NSB 
on T-gel which was less than 10% (NSB 1 unbound). Behaviour of the FITC-
transferrin conjugate injected onto the T-gel column (Fig.3.7.!) shows that the 
non-specific binding is also less than 10%. Excitation and emission spectra of 
FITC and conjugate ofFITC-transferrin are the same, at 4951525 nm (Fig.3.7.2). 
Using the same methods for the single BSA immunoassay (section 3.6), the results 
for the immunoassay of transferrin are shown in Table. 3.7.1 and Fig.3.7.3. 
Table 3.7.1 Single immunoassay for transferrin. 
25 Itl of sample was taken from a pre-incubation mixture of: 
1
1 :60FITC - transferrin, 100 Itl 
1:80 anti - transferrin, 100 Itl 
transferrin, 100 Itl with binding buffer 
then injected into the flowing system. 
[transferrin] Itglml fl int. (pk.a.) B/Bo % 
0.0 51.0 100.0 
2.0 47.9 94.0 
10.0 43.9 86.0 
50.0 37.8 74.0 
100.0 30.6 60.0 
150.0 27.6 54.0 
200.0 25.5 50.0 
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Fig.3.7.l Fluorescence profile of FIre-transferrin conjugate through T-gel 
column. ex/em = 495/525 nrn, slits 10/10 nrn, flow rate 4 mlImin. 
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Fig.3.7.2 Excitation and emission spectra of FITe (A and B) and FITe-transferrin 
(a and b). ex/em = 495/525 nm, slits 10/10 nm (concentration of the samples was 
unknown). 
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Fig.3.7.3 Calibration curve for transferrin immunoassay. ex/em = 495/525 nm, slits 
10/10 nm, flow rate 4 mlImin. 
3.8. Single Immunoassay for Theophylline 
Theophylline is a drug widely used for treatment of asthma (Chapter 1.5.4). The 
therapeutic concentration of theophylline in the blood serum is 8-20 Ilglml. 
Theophylline is a small molecule which has fluorescent excitation and emission at 
280 and 335 nm (Fig.3.8.l), but the spectra ofFlTC labelled conjugate are same as 
FlTC at ex/em = 495/525 nm. Theophylline and its FlTC conjugate (theophylline-
8 FlTC tracer conjugate was purchased from IGi, Gateshead, UK) did not show 
any significant NSB on the T-gel column (Fig.3.8.2). 
The method used for theophylline single immunoassay was the same as for 
albumin, except that the flow injection loop volume was changed to 100 III to 
increase the fluorescence intensity. The results are shown in Table 3.8.1 and 
I 
Fig.3.8.3. They show that theophylline can be determined in the therapeutic range, 
with the controls showing the using stability. 
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Fig.3.8.1 Excitation and emission spectra of theophylline. 
ex/em = 280/335 nm, slits 10/10 om. 
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Fig.3.8.2. Fluorescence profile of FITC-theophyJline on T -gel column. ex/em = 
495/525 nm, slits 10110 nm, flow rate 4 mlImin. 
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Table 3.8.1 Single immunoassay for theophylline. 
100 III of sample was taken from a pre-incubation mixture of: 
1
1: 10 FITC - theophylline, 5111 
1 :20 anti - theophylline, 10 III 
theophylline, 125 III with binding buffer 
then injected into the flowing system. 
[theophylline] nglml fl int. (pk.a.) BlBo% 
0.0 22.3 100.0 
1.0 21.6 97.0 
5.0 19.6 88.0 
10.0 15.8 71.0 
20.0 14.1 63.0 
50.0 9.6 43.0 
200.0 5.2 23.0 
1000.0 3.1 14.0 
. 
controlled concentration of theophylline 
[theophylline] nglml fl int. (pk.a.) BlBo % 
0.0 28.0 100.0 
3.0 24.1 86.0 
15.0 17.4 62.0 
75.0 11.5 41.0 
400.0 5.6 20.0 
C.V. % (n=4) 
2.3 
2.5 
2.1 
3.4 
1.9 
4.3 
3.8 
1.8 
! 
C.V. % (n=4) 
1.5 
3.6 
3.8 
3.3 
3.9 
note: the results of theophylline immunoassay and controlled c~ncentrations of 
theophylline were determined using same condition and same column but they 
were determined in the different day. 
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Fig.3.8.3 Calibration curve for theophylline immunoassay. ex/em = 495/525 nm, 
slits 10/10 nm, flow rate 2 rnlImin. 
3.9. Single Immunoassay for Hydrocortisone 
3.9.1 Introduction 
Hydrocortisone is a steroid honnone which has a phannacological action on almost 
every organ in the body (chapter 1, section 1.5.5). It is present in serum in minute 
concentrations and monitoring the therapeutic range for clinical use [11] requires a 
highly sensitive method. Hydrocortisone lacks functional groups (e.g. NH2, SH, 
COOH) with which to couple it directly with a protein or fluorescent dye. As is 
often the case in steroid immunoassays, the synthesis of a steroid derivative 
containing an additional functional group is necessary [12-13], producing for 
example a carboxyl group which is capable of coupling with amino residues in a 
protein molecule via the carbodiimide method [14-15]. 
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The water soluble carbodiimides e.g. l-ethyl-3-(3-dimethyl-aminopropyl) 
carbodiimide (EDAC) is widely used in coupling or conjugation reactions, because 
it is capable of forming amide bonds between carboxylic acids and amines by 
activating the carboxylate to form an amine-reactive intermediate, O-acylurea [16]. 
The intermediate then can be attacked by the amine or amino acid side chains in 
proteins in aqueous solution [17-18]. However this intermediate is unstable in 
aqueous solutions or in some cases the procedure is limited by lower coupling 
yields obtained under some conditions. Therefore this procedure can not be 
performed without stabilisation of the intermediate using N-hydroxysuccinimide 
(NHS) [19]. NHS is hydrophilic active ester which hydrolyse very slowly and can 
be used for covalent attachment of small molecules to proteins [20]. 
In this project, Hydrocottisone-21-hemisuccinate (Hydrocortisone-21-HS) was 
used instead of hydrocortisone for the immunoassay, because Hydrocortisone-21-
HS contains a carboxyl group which can react with EDAC to form an amine-
reactive intermediate, O-acylisourea. The carboxylized succinimidyl ester can be 
coupled to a carrier protein (BSA) in the presence of NHS. After the drug-protein 
conjugate was made it was then labelled with a fluorophore (e.g. it was labelled 
with Fluorescein and Rhodamine respectively). These could be used as labelled 
conjugates in the competitive fluorescence immunoassay. 
3.9.2 Procedure 
3.9.2.1 Principle ofthe Reaction 
The reaction scheme for synthesis of the FITCrrRITC-BSA-hydrocortisone-21-HS 
conjugate is shown in Fig.3.9.1. During the procedure the pH level, temperature, 
reaction time and the ratio of hydrocortisone-21-hemisuccinate to the carrier 
protein BSA were well controlled. Because the hydrocottisone-21-hemisuccinate 
is not soluble in a pH lower than 9.6, the reaction requires excess of 
hydrocortisone (hydrocortisone-21-hemisuccinate) [5]. 
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3.9.2.2 Process of the Reaction 
In the assay, hydrocortisone-21-HS was labelled with FITC and TRITC 
respectively. The molar reaction ratio of hydrocortisone-21-HS to BSA was 15:1, 
FITC or TRITC to BSA was 10:1 times in molar concentration. These ratios gave 
the best fluorescence response on the T-gel column. The conjugates were 
synthesised and characterised by following methods: 
step 1) 20 mg hydrocortisone-21-hernisuccinate was dissolved in 1.5 ml of 
carbonate buffer #2, pH 9.6, added to 0.05 mMol DEAC, then 0.1 
mMol NHS pre-dissolved in 0.5 ml of carbonate buffer #2. The 
mixture was stirred at room temperature for 20 min. 
step 2) 20 mg BSA was dissolved in 0.5 ml carbonate buffer #1 pH 9.3 then 
added to the solution flbove, the mixture was stirred at room 
temperature for 2 hours. 
step 3) 1.2 ml of 1 mglml FITC (dissolved in carbonate buffer #1 pH 9.3) or 
1.3 ml of 1 mglml of TRITC (50 ILl of methanol was added before 
dissolved in carbonate buffer #1 pH 9.3) then added into the above 
solution, the final mixture was stirred at room temperature for 1.5 
hours. 
step 4) a 10 ml PD-1O Sephadex G-25 column was used for purification of 
the reactants, the resulting solution was then stored at < 4 QC as a 
, 
stock solution. An example of purification profile is shown in Fig. 
3.9.2. 
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3.9.2.3 Controlling the pH level 
The pH level was dropped when NHS added into the solution. Unfortunately 
hydrocortisone-2l-HS was not soluble in a pH below 9.6, and coupling of protein 
to a fluorescent dye has to take place in a buffer with slightly basic pH, e.g. pH 
>8.0, but it can not be too high, e.g. pH > 10 as the protein will be denatured. 
Generally, the carbodiimde method is performed in a pH below 5.0 [16-20 and 
instructions from Pierce & Warriner Ltd] , therefore, during the process of 
conjugation, the pH levels should be carefully controlled in each step. The buffers 
which were used in this procedure is shown in Table 3.9.1. 
Table 3.9.1 Carbonate buffer ionic strength against pH changing when NHS was 
added. 1.0 ml of 0.5 mMol NHS was added in 10 ml of carbonate buffers 
individually. 
[ionic] 
buffer #1 
*buffer #2 
*buffer #3 
*buffer#4 
pH before 
9.6 
9.6 
9.6 
9.6 
pH after 
6.2 
9.6 
9.6 
9.6 
note: * the ionic strength in the carbonate buffers is 2 or 3 or 4 times higher 
than buffer #1. Buffer #1 is the original carbonate buffer for synthesis of protein 
conjugate pH 9.3 (section 3.1.1), ionic strength in buffer #1 is: 
NaHCO 2.9mg = 34.5 mMol Na CO 1.59mg = 150 mM I 
3 84.01 ,2 3 105.99 . 0 
100 
Chapter 3. Single Immunoassays 
o 0 H'C!· ~ 11" I Cf-t,,-Q-C- (CH,), - C -OH +CH"CHrN=C=N-(Cl-I:!b-N-CH3 
I 
CH ____ . OH CH. 
~ EDAC 
Hydrocortisone· .. 
hemisccucinate ~'CI" 
o N- (CH,h- N-CH, 
11 11 I 
HYdrocortisone.2>-C-O_p CH. 
hemisccucinate NH-CH,- CH. 
1 HO-~~NHS 
o 
H'CI· 
I 
HYdrocortisone-2> __ Lo_Nh 
hemisccucinate ~~ 
o 
N H-(CH,h-N-CI-I:J 
I I 
+ o=c CI-I:J ~H-CI-\rCI-I:J 
! H,N--BSA 
HYdrocortisone.2> __ ~_ NH -BAS 
hemisccucinate 
HO 
HO o 
N=C=S (or TRITC) 
CH. 
?i 90 
HN-C-(NH-C )-n CH2CH2-C-0-CH2 
" " S 0 
Fig.3.9.1 Reaction scheme for synthesis ofFITCrrRITC-BSA-hydrocortisone-21-
HS conjugate. 
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Fig.3.9.2. Fluorescence profile of purification of FITC-BSA-hydrocortisone 
conjugate. ex/em = 495/525 nm, slits 2.512.5 nm, flow rate 0.5 mlImin. 
3.9.2.4 Results 
The methods have been used for the albumin immunoassay in section 3.6 were also 
used for the hydrocortisone immunoassay. After the conjugates have been made, a 
UV -visible spectrometer was used to determine the absorbance(A) of the reagents 
and the conjugates, the results are shown, in Table 3.9.2 and Fig.3.9.3. The 
excitation and emission wavelengths of FlTC or TRITC are same at 495 and 525 
urn or 550 and 575 urn respectively and in effect are unchanged after conjugation 
to BSA-hydrocortisone-21-HS. Fig.3.9.4 shows the behaviour of TRITC-BSA-
hydrocortisone-21-HS conjugate on a T-gel column and some NSB occurs, 
assuming this was caused by hydrocortisone-21-HS because FITC, TRITC, BSA 
which show little NSB on a T-gel column (FITC-BSA-hydrocortisone-21-HS 
conjugate shows similar behaviour on the T-gel column). Also the conjugate of 
FITCITRITC-BSA-hydrocortisone-21-HS has been made reversal, the conjugate 
of FITC-BSA or TRITC-BSA was made first as normal fluorescence protein 
conjugate, the fluorescence dye labelled BSA was then" conjugated to the 
carboxyIized succinimidyl ester. There was not much different in the NSB and 
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fluorescence respond between these two procedures. The conjugate of BSA-
hydrocortisone-21-HS was labelled with TRITC was used in the hydrocortisone 
immunoassay and the controlled hydrocortisone-21-HS was used for measuring 
hydrocortisone levels, the results are shown in Table 3.9.3 and Fig.3.9.5. FITC 
labelled conjugate was also need in a hydrocortisone assay, the results are shown in 
Table 3.9.4 and Fig. 3.9.6. 
From the results it can be seen that: 
(1) from the UV absorbance, after the conjugate of TRITC/FITC-BSA-
hydrocortisone-21-HS has been made, the calculation of labelling efficiency of the 
conjugate is not possible, because the absorbance wavelengths of hydrocortisone-
21-HS (245 nm) and BSA (280 nm) are close (Fig.3.9.3) or the molecular 
structure changed during the conjugation. But a radioactivity counter might be 
used to count the exact amount of hydrocortisone-21-HS molecules having been 
conjugated to BSA. 
(2) during the process of the conjugation the pH level, temperature, reaction time 
and the molar reaction ratio of hydrocortisone-21-HS to BSA should be 
controlled. This experiment required 15:1 molar ratio ofhydrocortisone-21-HS to 
BSA, if a lower level than this ratio was used the conjugate was not produced. 
The experiment also show that even under the same conditions each time the 
fluorescence response and the NSB of conjugate were not constant. 
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TRITC 
~conjugate 
Fig.3.9.3.(a) DV/visible absorbance of albumin (BSA), TRITC, hydrocortisone-
21-hemisuccinate (cort), and the conjugate ofTRlTC-BSA-hydrocortisone-21-HS 
(conjugate). 
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Fig. Fig.3.9.3.(b) UV/visible absorbance of albumin (BSA), FlTC, 
hydrocortisone-21-hemisuccinate (cort), and the conjugate of FlTC-BSA-
hydrocortisone-21-HS (conjugate). 
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Table 3.9.2 Results ofUV/visible absorbance (A) of the conjugates. 
[sample] Iml "-<,00) = nm 
245 254 280 356 495 550 
hydrocortisone 21-HS 1.4 
50~g 
BSA200)lg 0.34 
FITC lO)lg 0.3 
TRITC25)lg 0.17 0.05 0.6 
cort-BSA-FITC 1:20 0.2 0.7 
cort-BSA-TRITC 1:20 1.6 0.1 0.4 
20,0 
n. 
illt.19.O 
18,(1 
17.0 
16.0 
15.0 
U.O 
13.0 
12.0 
11.0 
10.0 
•. , 
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Fig.3.9.4 Fluorescence profile of TRITC-BSA-hydrocortisone. ex/em = 550/575 
nm, slits 10/1 0 nm, flow rate 2.0 ml/min, injection loop loo)ll. The first peak is 
conjugate only, it has some NSB, the ratio of NSB/unbound = 4% (57/1410 pk.a.). 
The second peak is the same diluted conjugate with anti-hydrocortisone antiserum, 
the ratio of boundlunbound = 12.6% (157/1249 pk.a.), the bound peak is 8.6.% 
bigger than the NSB associated with first peak. FITC labelled conjugate has 
similar results with TRITC conjugate. 
106 
Chapter 3. Single Immunoassays 
Table 3.9.3 Single immunoassay for hydrocortisone. 
The conjugate ofhydrocortisone-21-HS-BSA was labelled with TRITC. 
100 /ll sample was injected onto the column taken from following mixture: 
1
1:100 TRITC - BSA - hydrocprtisone - 21- HS, 20/lI. 
1: 100 anti - hydrocortisoue - 21- HS, 15 /ll 
hydrocortisone - 21- HS, 105 /ll with binding buffer 
[hydrocortisone- fl int. (pk.a.) BIBO% 
21-HS] /lglml 
0.0 99.0 100.0 
1.0 97.2 98.0 
2.0 93.0 94.0 
4.0 83.1 84.0 
6.0 62.4 63.0 
8.0 43.6 44.0 
16.0 25.6 26.0 
controlled of hydrocortisone-21-HS /lglml 
1.0 151.5 99.0 
3.0 131.6 86.0 
5.0 91.8 60. 
10. 59.7 39.0 
16.0 30.6 20. 
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2.9 
2.3 
5.8 
2.9 
6.0 
2.9 
3.0 
4.5 
6.0 
4.9 
Chapter 3. Single Immunoassays 
Table 3.9.4 Single immunoassay for hydrocortisone. 
The conjugate ofhydrocortisone-21-HS-BSA was labelled with FITC. 
100 III sample was injected onto the column taken from following mixture: 
1
1: 100 FITC - BSA - hydrocortisone - 21- HS, 20 III 
1:100 anti - hydrocortisone - 21- HS, 20 III 
hydrocortisone - 21- HS, 100 III with binding buffer 
[hydrocortisone- fl int. (pk.a.) 
21-HSlllglml 
0.0 123.0 
1.0 222.0 
2.0 113.2 
4.0 98.4 
6.0 86.1 
8.0 73.8 
16 34.4 
BIBO% 
100.0 
99.0 
92.0 
80.0 
76.0 
60.0 
28.0 
!O8 
C.V.% 
n=4 
4.2 
5.0 
3.9 
3.8 
3.0 
5.2 
6.6 
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Fig.3.9.5 Calibration curve for hydrocortisone. Hydrocortisone-21-HS was 
labelled with TRITC, ex/em = 5501575 nm, slits 2.5/2.5 nm, fluorescence measured 
using Ft 4500 spectrometer, flow rate 2 mlImin, injection loop 100 f.l.l. 
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Fig.3.9.6 Calibration curve for hydrocortisone. Hydrocortisone-21-HS was 
labelled with FITC, ex/em = 4951525 nm, slits 2.512.5 nm, fluorescence measured 
using Ft 4500 spectrometer, flow rate 2 mlImin, injection loop 100 f.l.l. 
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Chapter 4. Dual Immunoassay 
4.1. Synchronous Spectroscopy Techniques 
Synchronous fluorescence spectroscopy provides a simple and convenient method 
for the simultaneous analysis of components of a mixture. The principles and 
techniques have been described in chapter 1 (1.2.3). In this chapter, methods in 
which albumin (BSA) and transferrin were labelled with Cascade Blue and FITC 
respectively are described. The two conjugates, unlabelled BSA and transferrin 
and their corresponding antibodies would be completely mixed in the same sample. 
Synchronous scanning combined with flow injection immunoassay can then be used 
for measuring BSA and transferrin simultaneously. The synchronous wavelength 
interval /:;.A, flow rate and stopped-flow time were controlled during the assay. 
Independent methods (using standard protein, and immunodiffusion) have been 
used to validate the dual immunoassay. 
4.1.1 Instrument Noise Checking for Synchronous Scanning 
Instrument noise, especially in fluorescence can adversely affect the instrument 
performance. Therefore, in any analysis instrument noise must be taken into 
consideration. It is possible to determine the level of noise by scanning a blank e.g. 
water or buffer, over the range required using synchronous scanning program 
available on the LS-50B spectrometer. From these initial findings the best 
instrument parameter were found to be slits of excitation and emission of 2.5 and 
2.5 nm and scan speed is 240 nm/min, these would be used throughout the project. 
4.1.2 Fluorescence Spectra and Synchronous Spectra of FITC and Cascade Blue 
A comparison of the fluorescence spectra of excitation and emission to the 
fluorescence signal of synchronous scan of FITC and Cascade Blue are shown in 
Fig. 4.1.1 and 4.1.2. 
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4.1.3 Choosing I!.'A 
The synchronous spectrum is dependent on both the excitation and emission 
spectra of a solute in a screen. Choosing a suitable I!.'A is thus an important first 
step for synchronous spectroscopy measurement. In this work, the synchronous 
scan range was set at 360-550 nm excitation monochromotor and a number of M 
values from 5-60 nm were selected. Each scan took about 47 seconds. 
To determine a suitable I!.'A value for a mixture of FlTC and Cascade Blue, equal 
concentrations (1.0 Ilg/ml) of FlTC and Cascade Blue were studied. From these 
experiments it was found that increasing by the I!.'A values was show higher 
fluorescence signal but with some overlap, I!.'A values of 10 nm found to give 
acceptable fluorescence intensities and the best spectral separation for this mixture 
(FigA.1.3). 
The same experiment was also performed for a mixture of Lucifer Yellow VS and 
FITC. The I!.'A values from 5-120 nm were selected, unfortunately there was no 
separation of synchronous spectra that was possible as the emission wavelengths of 
Lucifer Yellow and FITC was close together, 535 nm and 525 nm respectively. 
Also the fluorescence intensity of Lucifer Yellow is much lower than mc. 
4.1.4 Inteiference Between FITC and Cascade Blue 
Interference caused between the dyes is an important consideration in a mixture. 
To determine the interference of Cascade Blue on mc or FITC on Cascade Blue 
the following methods were used: 
In the first experiment, the FITC concentration was kept constant (1.0 IlglmI) and 
concentrations of Cascade Blue from 0.0 f-tglml to 3.0 f-tglml added. The resulting 
change in fluorescence intensities is shown in FigA.l.4. This process was then 
repeated in reverse i.e., the Cascade Blue concentration was kept constant (1.0 
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Ilg/ml) and FITC levels from 0.0 Ilglml to 3.0 Ilglml added, the resulting change in 
fluorescence intensities is shown in FigA.I.5. 
From the results it can be seen that: 
(1) the excitation and emission spectra of FITC and Cascade Blue are quite 
distinct, their fluorescence intensities are similar when they are at the same 
concentration. 
(2) the synchronous scan of FITC and Cascade Blue mixture shows that there is 
little interference between these two dyes in this type of spectroscopy (LlA 10 nm, 
slits 2.512.5 nm). 
Therefore FITC and Cascade Blue would be a good pair of labels to be used in 
dual immunoassays. 
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FigA.l.l Excitation, emission and synchronous spectra of FITC. ex/em = 
495/525 mu, slits 2.512.5 mu, synchronous signal at 500 mu, LlA at 10 mu (the 
spectra were measured using a same sample). 
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nm, (the spectra were measured using a same sample) . 
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Fig.4.1.3 Synchronous spectra of Cascade Blue and FITC. Slits 2.5/2.5 nm, 
!lA 10 nm. The concentration of Cascade Blue and FITC both were 1.0 flglml. 
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Fig.4.1A The calibration curves for interference between Cascade Blue and FITC. 
FlTC was kept constant (1.0 iLglmJ), the concentrations of Cascade Blue were 
from 0.0 to 3.0 Ilg/mJ, the t,.'A was set at 10 nm (saturation display range ofthe LS-
SOB < 1,000). 
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FigA.1.S The calibration curves for interference between Cascade Blue and FITC. 
Cascade Blue was kept constant (1.0 IlglmJ), the concentrations of FlTC were 
from 0.0 to 3.0 )lglmJ, the t,.'A was set at 10 nm (saturation display range of the LS-
SOB < 1,000). 
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4.2 Synchronous Scan Flow Rate Experiments 
The reasons and the methods for determination of flow rate were described in 
chapter 3 (section 3.3). The method used during the synchronous scanning flow 
injection analysis experiments is described below. 
In a typical experiment, either the FITC or Cascade Blue (it was not important) 
excitation and emission wavelengths were chosen for the spectrometer's time scan 
program and several flow rates (0.5-4.0 mlImin) were tested.· A sample of FITC-
transferrin and C.Blue-BSA conjugates with their antibodies was injected into the 
flowing stream. When the reactor-bound peak: reached its maximum intensities, 
the flow was stopped immediately. The spectrometer was then switched to the 
synchronous scan mode to measure the fluorescence intensity for both dyes. After 
that the flow was restarted and the column was equilibrated for next sample. 
The instrument parameters used for the time scan were: ex/em = 410/430 run 
(Cascade Blue), slits 10110 run, 100 III injection loop and a small glass reactor(3.5 
I . 
mm id. x 20 mm ) and for the synchronous scanning were: synchronous scan range 
360-560 run, slits 2.5/2.5 run, scan speed 240 nmlmin, dA 10 nm. Each time 
Cascade Blue and FlTC were measured at the constant wavelengths. The results 
are shown in Fig. 4.2.1. 
4.3 Synchronous Scan with Stopped Flow 
The synchronous scanning combined with flow injection analysis it may be possible 
to measure the fluorescence signals for a mixture of FITC and Cascade Blue for a 
dual immunoassay. But the stopped flow time required precisely control. The 
stopped flow time, which is the period of time from injection of the sample into the 
flowing stream until the reactor-bound peak reaches its maximum intensity. 
During the project, only a manual pump (Gilson Minipuls 2 or 3 peristaltic pump) 
was utilised in the flow injection system and it was found that it was not possible to 
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stop the flow accurately. This meant that the fluorescence intensity which was 
recorded by the synchronous scan, was not always the same concentration in the 
flow cell as in the time scan, e.g. if the flow was stopped early the area of the 
stream which contained the highest concentration of the compound in the sample 
will have not reached the flow cell, so the fluorescence intensity would not be at a 
maximum when it was measured, if the flow stream was stopped later, the highest 
concentration in the sample would have passed through the flow cell already. 
Various stopped flow times with a fixed flow rate (2.0 mlImin) were investigated. 
The flow which was stopped at 2 minutes and 22 seconds (142") with the flow 
rate at 2.0 mlImin, after the sample was injected to the flowing stream gave the 
highest fluorescence response on the synchronous scan with the flow injection 
experiments (Fig. 4.3.1) and this time would be used throughout the dual 
immunoassay. 
fl.lnt. 10 
(pk.a.) 
8 
• 
BSA 
6 • FITe 
4 
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o 
0.5 1.0 2.0 3.0 4.0 
flow rate m!Jmjn 
Fig.4.2.1 Flow rate against fluorescence response. Flow rates were examined on 
time scan program, ex/em = 410t430,urn (C.Blue), slits IOtIO,urn, 100 III injection 
loop, synchronous scan range from 360 urn to 550 urn, slits 2.5/2.5 urn, scan speed 
240 nrn/min, 6.f.. 10 nm. 
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Fig.4.3.1 Fluorescent response against the stopped flow time. Flow rates were 
examined on time scan program, ex/em = 410/430 om (C.Blue), slits 10110 om, 
100 III injection loop, synchronous scan range from 360 nm to 550 nm, slits 2.5/2.5 
nm, scan speed 240 nm/min, b.fv 10 nm. 
4.4 The Conjugates to Antibodies Ratios 
As described in chapter 3 (section 3.4), the right ratio of each conjugate to its 
corresponding antibody is required for each analyte in a dual assay: normally this is 
the ratio which would give the highest assay sensitivity. The method of 
deterruining the ratios for the dual assay was similar to that described for single 
immunoassays, except that while one conjugate was examined with its antibody, 
the second conjugate with the corresponding antibody was also present at a 
constant level. When the conditions required for the C.Blue-BSA conjugate were 
investigated, the FITC-transferrin (e.g. 1 :20) and anti-transferrin antibody level 
(l :40) were kept constant in the samples which contained: 
\19 
1 :20 FITC - transferrin, 80)11 
1 :40 anti - transfenin, 80 III (1) 
1: 10 C. Blue - BSA, 100 III 
1: 10 -1: 100 anti - BSA, 100)11 
1 :20 FITC - transferrin, 80)11 
1 :40 anti - transferrin, 80 III (2) 
1:10anti-BSA,100).l1 
1:10-1:100 C.Blue -BSA, 100 III 
Chapter 4. Dual Immunoassay 
This procedure was then repeated for the FlTC-transferrin conjugate, with the 
C.Blue-BSA (1 :20) and the anti-BSA antibody (1 :40) kept at constant level which 
contained: 
(1) 
1 :20 C. Blue - BSA, 80).l1 
1 :40 anti - BSA, 80).l1 
1: 10 FITC - transferrin, 100).l1 
1: 1 0 -1: 100 anti - transferrin, 100)11 
1 :20 C.Blue - BSA, 80)11 
1 :40 anti - BSA, 80 III (2) 
1: 10 anti - transferrin, 100)11 
1: 10 -1: 100 FITC - transferrin, 100).l1 
In all cases the flow rate was set at 2.0 mllmin, the stopped flow time was 2 
minutes and 22 seconds. The optimum ratios of conjugates of C.Blue-BSA and 
FITC-lransferrin to their antibodies were found to be: 
{
1:lOc.Blue- BSA v 1:20 anti - BSA 
1: 10 FITC - transferrin v 1 :40 anti - transfenin 
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4.5 Antibodies Cross Reaction 
Immunoassays are designed as a highly specific technique, the antibody reagent 
producing a measurable response only for the analyte of interest. However many 
proteins have closely related structures with highly conserved epitopes, e.g. steroid 
hormones have very closely related structures which inevitably cause antibody 
cross reactivity in a assay, with similar problems occurring in therapeutic drug 
monitoring with cross-reactivating between drugs and their metabolites [1]. 
Therefore an investigation into the specificity and cross-reactivity of antibodies is a 
important part of any immunoanalytical technique. 
Cross-reactivity is a measure of antibody response to both the analyte and another 
substance in the sample. There are several methods available to examine cross-
reactivity, but competitive assays are the most common, involving the spiking of an 
analyte free matrix with the potentially cross-reactive substance. 
To investigate the effect of cross reactivity of anti-BSA with transferrin (i.e. the 
ability of the anti-BSA antibody to recognise both BSA and transferrin), BSA and 
transferrin were separately added to a reaction mixture which was specifically 
designed for anti-BSA-albumin (BSA) assay. A calibration curve was produced 
for BSA and for unlabelled transferrin, the results are shown in Fig.4.5.1. 
The experiment was then repeated for the anti-transferrin antibody with addition of 
, 
unlabelled BSA. The results are shown in Fig.4.5.2. 
Equation (4-1) [2] was used for the calculation of cross reactivity between 
antibodies of BSA and transferrin: 
'" . . concentration of analyte giving 50 % B / BO% 
70 cross reactIvIty =:: 
concentration of cross reactant gi ving 50% B / B % 
(4-1) 
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-0- BSA 
..... Transferrin 
Fig.4.5.1 Calibration curve for anti-BSA antibody cross reactivity to transferrin. 
Time scan, ex/ern = 410/430 run, slits 10/10 nrn, flow rate 2.0 rnlImin, for the 
synchronous scan, slits 2.5/2.5 nrn, stopped flow time 2'22", 11'A 10 nrn. 
B/BO 
% 100 
80 
60 
40 
o 1 2 3 4 
[Transferrin/BSA] mg/ml 
-0-- BSA 
..... Transferrin 
Fig.4.5.2 Calibration curve for anti-transferrin cross reactivity to BSA. Time scan, 
ex/ern = 410/430 run (C.Blue), slits 10/10 run, flow rate 2.0 rnlImin, for the 
synchronous scan, slits 2.5/2.5 nrn, stopped flow time 2'22", 11'A 10 nrn. 
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From the results it can be seen that the cross reactivity of anti-transferrin to BSA 
or anti-BSA to transferrin were very low, therefore antibodies of BSA and 
transferrin have no cross reactivity problems. 
4.6 Simultaneous Dual Immunoassay 
4.6.1. Duallmmunoassay 
In the dual immunoassay for transferrin and BSA, the sample contained a mixture 
of C.Blue-BSA and FITC-transferrin, antibodies of BSA and transferrin, and 
,r 
unlabelled analytes of BSA and transferrin, Two competitive reaction were thus 
occurred simultaneously during the assay, A schematic diagram of the 
synchronous scanning technique combined with flow injection immunoassay for 
simultaneously measuring BSA and transferrin in a mixture is shown in Fig.4.6.1. 
The sample was pre-incubated for 5 minutes at room temperature before injection 
into the flowing stream with binding buffer using the time scan program, after 2 
minutes and 22 seconds the flowing stream. was stopped and the bound peaks 
scanned by the synchronous scanning method. Each time the fluorescence intensity 
of Cascade Blue and FlTC were measured at the constant wavelengths and the 
results calculated as described previous in the single immunoassay (section 3.6,). 
Generally each sample took 4 minutes including the 2'22" for time scanning, 47" 
for synchronous scanning and 59" for reactor re-equilibration and the time for 
changing the programs. The results are shown Table 4.6.1 and in Fig.4.6.2. 
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Table 4.6.1 The dual immunoassay for albumin (BSA) and transferrin. 100 III sample 
was injected to the flow injection system taken from the following mixture: 
[BSA! 
transferrin I 
Ilglml 
0.0 
20.0 
40.0 
50,0 
100.0 
400.0 
800.0 
BIBO 
% 100 
80 
60 
20 
1:10 Cascade Blue-BSA, lOO III 
1:20 anti - BSA, 100ml 
1:10 FITC - transferrin, l00!Jl 
1:40 anti - transferrin, 100 III 
BSA + transferrin, 100 III 
BSA 
fl int. BIBO% .C.V.% fl int. 
11.9 100,0 6.7 10.8 
11.7 98.0 7,5 10.7 
11.4 96,0 6.7 10.2 
10.7 90.0 704 9.9 
9.5 80,0 7.5 8,6 
8.1 68.0 804 8.6 
6.9 58,0 5,8 7.2 
100 
[BSAltransferrin lllglml 
transferrin 
,BtBO% C.V.% 
100,0 7.5 
99.0 7,6 
94,0 7.3 
92,0 5.7 
86.0 7.5 
76,0 5.2 
65.0 5,6 
-0- SAS 
--- transferrin 
FigA.6.2 Calibration curves for the dual immunoassay. Time scan, ex/em = 410/430 om 
(C,Blue), slits 10/10 nm, flow rate 2.0 ml/min, synchronous scanning, scan range 360-550 
nm, slits 2,5/2.5 nm, stopped flow time 2'22", scan speed 240 nm/min, fit.. 10 nm. 
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4.7. Other Methods Used for Immunoassays 
4.7.1. Using Standard Proteins 
4.7.1.1 Serum Standard Curve 
It is important in fluorescence immunoassay to considering the effect of increasing 
the concentration of protein or fluorescence has on the performance of the assay. 
The controlled protein (standard protein) was purchased from Sigma (Poole, 
Dorset, UK) which contains of human essential normal concentrations of serum 
proteins fractions. Assuming 50 mg/ml of albumin (HSA) (61 % of albumin, 2-3% 
of transfenin and 40% of antibodies assigned value) in the controlled protein. In 
this experiment the controlled protein was used instead of BSA and conjugate of 
Cascade Blue-BSA were used as the samples, they were diluted in a range of 
concentrations and the fluorescence intensities were measured using synchronous 
scan spectroscopy. Table 4.7.1 and Fig.4. 7.1 show the results of the 
concentrations effect on the fluorescence intensities. 
fl 260 
inl 240 :: 
220 
..... alb 
200 
180 
160 
140 
120 
100 
80 
60 
40 
20 
0 
0 5 10 15 20 25 30 
[albunin] mglml 
Fig. 4.7.1 Calibration curve for albumin (HSA) (in controlled protein) 
concentrations against fluorescence. 
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Table 4.7.1 The concentrations of HSA and conjugate against to their 
fluorescence corresponding. Synchronous scan range 250-450 nrn, slits 2.5/2.5 
nm, scan speed 240 nm/min, 1:J.'A 10 nm, the sample were using deionised water. 
[HSA] mglml fl int. 
(pk.h.) 
0.0 0.0 
0.1 30 
0.2 56 
0.5 108 
1.0 135 
2.0 180 
4.0 215 
6.0 231 
8.0 240 
10.0 243 
12.0 244 
14.0 239 
16.0 234 
18.0 222 
20.0 217 
22.0 205 
24.0 200 
26.0 189 
28.0 180 
30.0 175 
[C.B-BSA] 
diluted 
1:2000 
1:1000 
1:800 
1:600 
1:400 
1:300 
1:200 
1:150 
1:100 
1:80 
1:60 
1:40 
1:20 
1:10 
1:8 
1:4 
1:2 
1:1 
35 
69 
92 
116 
173 
237 
348 
450 
672 
840 
fl int. 
(pk.h.) 
> 1000 
> 1000 
> 1000 
> 1000 
> 1000 
> 1000 
960 
900 
From the results it can be seen that the fluorescence intensities are only affected by 
the samples (albumin and conjugate) are at lower concentrations, therefore it can 
be suggested that in practical samples are required diluted before any measuring. 
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4.7.1.2 Using Controlled Proteins 
Generally, in real clinical analysis, the unknown samples come from patients' 
serum. The controlled protein which contains concentrations of albumin (HSA) 
and transferrin fraction compare with normal human serum. In this case the 
controlled protein was used instead of bovine serum albumin (BSA) and transferrin 
to compare the results which were presented using single and dual immunoassays 
models. 
In this experiments, the controlled protein was diluted using deionised water. The 
controlled protein which contains 50 mglml of HSA and 2-3 % of transferrin was 
diluted in a range from 0.0-2000.0 Ilglml for albumin (HSA), but the 
concentrations of transferrin must be much less than the same volume for the 
albumin. Fig. 4.7.2 shows the results of HSA which was used to compare BSA in 
the single immunoassay. Fig.4.7.3 show the results of transferrin (using HSA) 
which was used to compare transferrin in the single innnunoassay. Fig.4.7.4 show 
the results using controlled protein to compare BSA and transferrin in dual 
immunoassay. 
4.7.2 Immunodiffusion Method 
Immunodiffusion method is also an immunochemical method except the analyte 
and the antibody reaction is performed in gels which is based on 
immunoprecipitation rather than in liquid media. The precipitation reaction occurs 
where the diffusing components meet. Agar or agarose gels are most common gel 
media used for immunodiffusion analysis. For the immunodiffusion method, the 
agarose is poured on to an appropriate support to which antibody and analyte are 
applied to diffuse into the gel. Depending on the type of application, only one 
(single immunodiffusion) or both (dual immunodiffusion) components can diffuse 
[3]. 
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Single immunodiffusion is a basic method for the quantitative determination of 
analytes. At this stage of the project, a single radial immunodiffusion method was 
utilised to compare the results which was provided by the single immunoassays. 
The experiment was performed on glass plates onto which hot (54°C) 1.5% 
agarose solution containing a suitable concentration of antibody (1 :400 anti-BSA 
or I :40 anti-transferrin in separate glass plates) was poured. The agarose solution 
was prepared using tris-tricine lactate buffer, pH 8.6, after cooling and 
solidification, circular wells were cut in the gel, then a range of concentrations 
analyte (HSA, BSA and transferrin) solution were pipetted. The plates were 
placed in a humidified chamber at 4°C to prevent the agarose drying. During the 
procedure, the analyte was the only component that can diffuse in to the agarose. 
After a few days, the analyte had diffused radial and produced precipitation rings 
after its interaction with the antibody. The higher concentration of analyte would 
produced the larger diameter of the precipitation ring. The precipitation rings 
could be measured with the naked eye or stained. The diameters or areas of 
precipitation rings were plotted as a curve against the corresponding analyte 
concentrations. The results using HSA in controlled protein, BSA and transferrin, 
with anti-BSA and anti-transferrin are shown in Fig.4.7.5 and Fig.4.7.6. 
4.7.3 Comparison of Immunoassays to Immunodifusion Methods 
Both methods are based on the antigen-antibody reaction. The competitive 
immunoassay uses a known amount of labelled, unlabelled analyte and antibody, 
which are then incubated for a period of time. The labelled and unlabelled anlyte 
compete for the limited amount of antibody binding sets. When the concentrations 
of unlabelled analyte is increased this results in displacement (BlBo %) which can 
be plotted as a decreased calibration curve (standard curve) against the 
corresponding analyte concentrations. If an unknown sample is examined using 
this method, it is possible to determine its concentration by use of the standard 
curve. 
129 
Chapter 4. Dual Immunoassay 
Single immunodifuion methods use a known amount of antibody mixed with 
agarose gels and a known amount of analyte is pipetted into the wells, then the 
reaction occurs when the analyte diffuses into the antibody containing gels. When 
the concentrations of analyte is increased, the increased precipitation rings can be 
plotted in an increased liner calibration curve (standard curve) against the 
corresponding analyte concentrations. Therefore the result of a precipitation ring 
from an unknown sample will plotted against a concentration from the standard 
curve associated with the precipitation ring. 
In Fig. 4.7.2-4.7.6 the same concentrations of anti-BSA, BSA and HSA were 
measured using both methods. A comparison of these two methods, even though 
their results were presented in different showed similarity when measuring 
unknown samples. 
From the results it can be seen that: 
(l) using same concentrations (400 !Lg/m!) of BSA and HSA (in controlled 
protein) for the single and dual immunoassays, their displacement (BIBo %) are 
quite closed at 54%, 59% and 63 % respectively. HSA concentration could be 
36.6-50 mg/m! in normal human serum (61 % of albumin assigned value in 6-8% 
total weight proteins), in these experiments, assuming concentration of HSA is 50 
I 
mg/m!, perhaps the albumin concentration in this controlled protein does not 
contain as much as it is assumed. 
(2) in FigA.7.3 there is only some of displacement for transferrin in controlled 
protein comparing to transferrin assay, because the concentration of transferrin (2-
3% in the total weight protein) is much lower than the same volume of HSA in the 
controlled protein, and in these experiments the concentration of transferrin was 
prepared for HSA. 
(3) the anti-BSA was used through the experiments for the HSA-anti-BSA 
reaction, showed reasonable results, this meant that the anti-BSA antiserum has 
strongly cross-reactive with HSA. 
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(4) Comparison of the flow injection fluorescence immunoassays (FIA) to the 
single immunodiffusion, shows that the PIA immunoassays could be used for 
quantitative determination analytes with more variety forms. 
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BfBO 
% 100 
-0- BSA 
90 
--.- HSA 
80 
70 
60 
50 
40 [BSAlHSAlllglmI400 
FigA.7.2 Calibration curves for comparison of HSA (in controlled protein) to 
BSA in single immunoassays. These two curves are two single immunoassays 
overlapped, one is BSA assay, the other is HSA. ex/em = 410/430 nm, slits 10/10 
nm, flow rate 4.0 rnl. The samples contained: 
1
1:20 C.B1ue -BSA, 100 III 
1:400 anti - BSA, 100 III 
BSA, 50 III 
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1:400 anti - BSA, 100 III 
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400 [transferrinIHSA] Jlglml 
Fig.4.7.3 Calibration curves for comparison of transferrin (using RSA) to 
transferrin in single immunoassays. These two curves are two single 
immunoassays overlapped, one is transferrin, the other is transferrin using RSA in 
controlled protein. ex/em = 495/525 nm, slits 10/10 nm, flow rate 4.0 mI. The 
samples contained: 
1
1:20 FITC - transferrin, 100 III 
1 :400 anti - transferrin, 100 III 
transferrin, 50 III 1
1 :20 FITC - transferrin, 100 III 
1 :400 anti - transferrin, 100 III 
RSA, 50 III 
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8/80 
% 100 
--0- alb (HSA) 
90 
--e- trans(HSA) 
80 
70 
o 
60 
50 
40 400 [RSA 1 J.tglml 
Fig.4.7.4 Calibration curves far albumin (HSA) and transferrin in the dual 
immunaasssay using controlled protein. For time drive, ex/em = 410/430 nm, slits 
10/10 nm, flow rate 2.0 mlImin, for synchronous scanning, scan range 360-550 nm, 
slits 2.5/2.5 nm, scan speed 240 nm, stopped flow time 2'22", !lA 10 nm. The 
samples contained: 
1:20 C.Blue - BSA, 100 J.ll 
1 :400 anti - BSA, 140 J.ll 
1 :20 FITC - transferrin, 100 J.ll 
1:400 anti- transferrin, 140 J.ll 
HSA, 70 J.ll 
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[BSAIHSA] ~glml 
Fig.4.7.5 Calibration curves for comparison of RSA to BSA in single 
immunodiffusion method. These two curves were two single immunodiffusion 
methods overlapped, one was BSA ( __ e __ ), the other was HSA (--x--) in the 
controlled protein. The experiments were performed on two glass plates 
separately which the 100 III of 1:400 anti-BSA in 15 ml of 1.5 % agarose was 
poured. In glass plate #1, the analyte was BSA, each sample contained 2 III BSA 
with 150 III tris-tricine lactate buffer, pH 8.6, 4 III of sample was pipetted in to the 
circular wells individual. In glass plate #2, the analyte was HSA, each sample 
contained 2 III HSA with 150 III tris-tricine lactate buffer, pH 8.6, 4 III of sample 
was pipetted in to the circular wells individual. 
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Fig.4.7.6 Calibration curves for comparison of HSA to transferrin in single 
immunodiffusion method. These two curves were two single immunodiffusion 
methods overlapped, one was transferrin (--x--), the other was HSA (--e-_) in the 
controlled protein. The experiments were performed same as in Fig.4.7.5, except 
that the analytes and antibody were used anti-transferrin, transferrin, and HSA. 
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Chapter Five 
MULTI-ANALYTE AND MULTIPLE FLUORESCENCE 
SPECTRA INVESTIGATION 
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5.1 Multiple Fluorescence Spectra 
In conventional fluorescence spectroscopy techniques have limitations for the 
simultaneous detection of multiple fluorescence signals in a complex sample 
because the spectra overlap strongly. In this chapter several fluorescence 
spectroscopy techniques and software systems have been investigated to solve the 
problems in a multi-analyte immunoassay and multiple fluorescence spectroscopy. 
Three analytes were labelled with different fluorophores and used to investigate the 
multi analytes detection systems available. 
5.l.1 Synchronous Fluorescence Spectra 
Synchronous fluorescence spectroscopy and tlie techniques have been described in 
chapter 1 (section 1.2.3). The fluorescent intensity of a synchronous spectrum is 
normally similar or less than that of the excitation and emission spectra (Fig.4.1.1). 
This technique was combined with flow injection analysis to develop a dual 
immunoassay (chapter 4). It is also possible to utilise the technique for 
simultaneous measurement of more than two analytes. With three assays in the 
same sample, one problem will be to ensure that the combined assays still provide 
the sensitivity proved by the single assays. 
5.1.2 Quant Computer Program 
The Quant+ computer program is software specifically designed for the LS-50 
fluorescence spectrometer. It is a chemometric software package suitable for 
multicomponent spectroscopic analysis. Traditional spectroscopic methods for 
multicomponent quantitative analysis demand isolated peaks for each component 
of interest of all species in the sample. Quant does not have this limitation and 
provides a choice of multivariate calibration algorithms, PCR (principal 
components regression) and PLSl and PLS2 (different partial least squares 
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methods). Therefore Quant+ should be suited to quantify components of the 
spectra of mixtures. 
In this multi-analyte immunoassay, there are three different fluorophores and the 
experiment has to be combined with the flow injection analysis system. Before 
developing an assay, a mixture of Cascade Blue, FITC and TRITC was studied on 
the flow injection analysis system and the data analysed using the Quant+ program. 
During the experiment, it was found that the data from the time scan were not able 
to inspect the three mixed fluorophores in the sample. Reasons for this were (I) 
these three fluorophores' wavelength were very different, choosing one's 
wavelength could not cover the other two. (2) the Quant program is a software 
suitable for mUlticomponent analysis but with single spectrum or ones which has a 
strong overlap. For this reason the synchronous scanning technique perhaps might 
be used with a large !:it... after the time scan, this could increase the fluorescence 
intensity with some overlap, then the data can be analysed on the Q+ program, but 
the process would be very slow. Therefore the mixed of Cascade Blue, FITC and 
TRITC due to their well separated spectra were not suitable for using the Quant+ 
program. 
5.1.3 3-Dimension Scanning 
The ability to perform a 3-dimensional fluorescence scan ("3-D scan") is one of the 
programs provide on the F4S00 fluorescence spectrophotometer. A 3-D scan has 
one axis which represents the excitation wavelength, a second axis represents the 
emission wavelength, and the third axis represents the intensity. This gives a 
complete description of the fluorescence behaviour of a sample. Therefore if the 
excitation and emission wavelengths are set to over the range 200-800 nm, all the 
information from the various fluorophores in a complex sample would be plotted. 
A mixture of Cascade Blue, FITC and TRITe was examined in a conventional 
cuvette using a 3-D scan (Fig.S.l.1). The intensities of the three single 
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fluorophores and the mixture were similarly measured using the 3-D scan 
(Fig.5.1.2). During these experiments, all the fluorophores were studied at the 
same concentrations. From the results it can be seen that: 
(1) it is possible to use the 3-D scan program for the measurement of a mixed 
fluorescence sample. But there were some problems associated with this program 
which would limit its application in flow injection immunoassays. Each sample 
takes around 4 mines to scan. So, if the 3-D scan program was combined with the 
flow injection analysis system, the process would be similar to the synchronous 
scan technique, but the stopped flow time would be much greater, therefore the 
rate of analysis would be slow. 
(2) Fig.5.1.2 shows the comparison of the intensity from a single dye with that of 
the same dye in the mixture, in Fig 5.1.1 there is some overlap between FITC and 
TRITC, presumably because the emission wavelength of FITC, (525 run ) is close 
to the excitation wavelength of TRITe (550 nm). Therefore, the 3-D scan was not 
suitable for the multi-analyte flow injection analysis immunoassay. 
5.1.4 F4500 Fluorescence Spectrophotometer Intracellular Cation Measurement 
The F4500 fluorescence spectrophotometer intracellular cation measurement 
(F4500 IC) system is a specially designed program which is able to simultaneously 
measure up to 4 different fluorescence spectra. In a complex mixture, the 
wavelengths of excitation and emission are pre-set in order (e.g. from first to 
fourth of the fluorophores), then all the individually fluorophores in this mixed 
sample will be simultaneous scanned and the spectra will be plotted on the screen. 
Not only the fluorescent intensities of the mixtures are directly shown on the 
screen in the individually spectrum, but also this program can be combined with the 
flow injection analysis system. An example of analysis of a mixture of Cascade 
Blue, FITC and TRITC is shown in Fig.5.1.3. 
The conditions for this experiment were (they were used through the project): the 
instrument parameters: response level 0.1 sec, slits ex/em = 2.5/2.5 run, the flow 
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injection system: transmission tube d = 0.8 mm, flow rate 2.0 mlImin, the 
fluorescence signal appeared after the sample was injected 9 seconds and the 
samples were injected at every 90 seconds. 
So the flow velocity = 6.67 cm/sec (V = Q/A = 2.0 ml min-I/ 50 x 10-4 cm2 = 6.67 
cm/sec ), and the linear flow rate = 0.67 cm/sec (S = T X V = 0.1 sec x 6.67 
cm/sec). 
In theory when a sample is scanned it should be scanned at a single point, so every 
component in the mixture is scanned in order, but the fluorescence intensity is not 
changed. In this experiment the mixture of C.Blue, FITC and TRITC was scanned 
at different times in a continuous flow system. When the mixture is measured 
which is scanned on a 0.67 cm section not on a single section. This mixture is a 
well mixed sample, in such a short response time (0.1 sec) the intensity of C.Blue 
might be pure in the peak of C.Blue due to the wavelength of C.Blue is well 
separated from FITC or TRITC, but the intensity of FITC (or TRITC ) may not be 
pure FITC (or TRITC) in the peak of FITC (or TRITC) it may be mixed with 
some of TRITC (or FITC) in the peak due to their wavelength close, but the 
interference should be very small. 
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Fig.5.1.l 3-D scan of mixture ofC.Blue, FITC and TRITC. The right side of the 
pictures show the fluorescence excitation and emission spectra of TRITC which 
obtained as cross-section of the cursor. 
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Fig.5.1.2.A The single and the mixture of fluorophores were measured using 3-D 
scan without the flow injection analysis system. The fluorophore in a pure or a 
mixed sample was kept in same concentrations. Scan range of excitation and 
emission 300-700 run, slits 2.5/ 2.5 nrn and scan speed 3,000 nmlmin. This is a 
comparison of Cascade Blue in a pure sample (--e--) and in a mixture (--x--). 
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Fig.5.1.2.B 3-D scan intensity of FITC in a pure sample (--e--) and in a mixture 
(--x--). Other conditions were same as in Fig.5.1.2.A. 
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Fig.5.1.2.C 3-D scan intensity of TRITe in a pure sample (--x--) and in a mixture 
(--e--). Other conditions were same as in Fig.5.1.2.A. 
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Fig.5.1.3 Fluorescence profile of the mixture of C.Blue, FITC and TRITC 
measured on F4500IC which was combined with a flow injection system but 
without T -gel column. The highest peak (1) is C.Blue, ex/em 410/430 nm, the mid 
peak (2) is FITC, ex/em 495 1525 nm, and the smallest peak (3) is TRITC, ex/em 
550/575 nm, (the concentrations of sample was unknown). 
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5.2 Fluorescence Spectra: Interference 
The fluorescence interference was investigated for a mixture of Cascade Blue, 
FITC, TRITC, BODIPY and Cy5. There is little interference between Cascade 
Blue and F1TC (chapter 4, 4.1.4). In these experiments, Cascade Blue and F1TC 
were kept in constant and concentrations of TRITC, BODIPY and Cy5 were 
changed. All the experiments were performance on F-4500 spectrometer. 
5.2.1 Testing Conventional Fluorescence spectra 
Before any development study, all the fluorophores were not only scanned on their 
own specific spectra individually, but also they were scanned on others 
wavelengths, e.g. Cascade Blue was not only scanned on the wavelengths of ex/em 
= 410/430 nm, but also scanned on the wavelengths ex/em = 495/525 nm (FITC), 
540/570 nm (BODIPY), and 645/668 nm (Cy5). It was found that: 
(I) alI the fluorophores, the spectra of excitation and emission were only apparent 
on their specified spectra. 
(2) no specific interference. 
5.2.2 Testing Synchronous Spectra 
All the fluorophores were measured on the synchronous scan program and 
performance in a static cell without a flow injection system. The wavelength range 
of synchronous scan was set at 340-720 nm, slits 2.5/2.5 nm, scan speed 240 
nmlmin, .11.. 10 nm. 
146 
Chapter 5. Multi-analyte and Multiple Fluorescence Spectra Investigation 
5.2.2.1 Mixtures of Cascade Blue. FITC and TRITC 
The excitation and emission wavelength of TRITC is 550/570 run. In this 
experiment, fluorescence interference of TRITC to Cascade Blue and FlTC was 
investigated, the results are shown in Fig.5.2.1. 
5.2.2.2 Mixtures of Cascade Blue. FITC and BODIPY 
The excitation and emission wavelength of BODIDY is 540/570 run. In this 
experiment, fluorescence interference of BODIPY to Cascade Blue and FITC was 
investigated, the results are shown in Fig.5.2.2. 
5.2.2.3 Mixtures of Cascade Blue. FITC, TRITe and Cy5 
The excitation and emission wavelength of Cy5 is 645/668 nm. In this experiment, 
fluorescence interference of Cy5 to Cascade Blue, FlTC and TRITC was 
investigated, the results are shown in Fig.5.2.3. 
Fig.5.2.1 Fluorescence "'" 
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5.2.3 Testing F-4S00IC Spectra 
Fluorescence interference was investigated for the mixed of Cascade Blue, FlTC, 
TRITC, BODIPY and Cy5 using F-4500IC program. All the experiments were 
combined with a flow injection system but without the T -gel solid phase column. 
The excitation and emission wavelength of Cascade Blue were set at 403/430 nm, 
FlTC 4951525 nm, RITC 5501575 nm, BODIPY 5401570 nm and Cy5 645/668 
nm, slits were 2.512.5 nm, flow rate was 2.0 mlImin. 
5.2.3.1 Mixtures of Cascade Blue. FITC and TRITC 
Fluorescence interference of TRITC to Cascade Blue and FITC was investigated, 
the results are shown Fig.5.2.4. Also concentrations of the samples were kept in 
constant but the order of measurement was changed, the results are shown in Table 
5.2.1. 
5.2.3.2 Mixtures of Cascade Blue. FITC and BODIPY 
Fluorescence interference of BODIPY to Cascade Blue and FITC was 
investigated, the results are shown in Fig.5.2.5. Also concentrations of the samples 
were kept in constant but the order of measurement was changed, the results are 
, 
shown in Table 5.2.2. 
5.2.3.3 Mixtures of Cascade Blue. FITC, TRITC and CyS 
Fluorescence interference of Cy5 to Cascade Blue, FlTC and TRITC was 
investigated, the results are shown in Fig.5.2.6. Also concentrations of the samples 
were kept in constant but the order of measurement was changed, the results are 
shown in Table 5.2.3. 
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The results shown above, show that: 
1) Q+ program is only suitable for the mUlti-component analysis with single 
wavelength. 
2) 3-D scanning is a simple, direct fluorescence measuring technique. The 
fluorescence intensities are not changed even if the fluorophore is in a single or in a 
mixture sample, but this method is not suitable for a flow injection analysis 
immunoassays due to the scan takes long time. 
3) the single or mixed fluorophores were measured on the F-4S00IC, their 
fluorescence intensities and the C.V. remained in all conditions. 
4) both of F-4S00IC and synchronous fluorescence measuring systems show that 
Cascade Blue and FITC have little interference between each other, CyS has little 
interference to Cascade Blue, FITC but shows some interference to TRITC, 
TRITC or BODIPY shows some interference to FITC, due to the emission 
wavelengths being close. 
S) F-4S00IC is a sensitive, simple and quick technique especially as no stopped 
flow time is required. At this stage, the F-4S00IC fluorescence measuring 
programme combined with the flow injection analysis system provides a ideal 
method for the multi-analyte immunoassays. But also this program combined with 
a stopped flow experiment is suggested because this may increase the sensitivity of 
the assay. 
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Table 5.2.1 Fluorescence interference tested for the mixed of Cascade Blue, FITC 
and TRITC using F-4500IC program. The concentrations of the fluorophores 
were kept in constant but the samples were measured under different conditions. 
Firstly there was only single fluorophore in the sample, then two fluorophores were 
mixed in the sample, finally three fluorophores were mixed in the sample. The 
order in which they were measured was also investigated. 
fl int. C.V.%=6 measuring order 
C.B FITC TRITC C.B FITC TRITC 
single fluorophore in the sample 
30 87 50 11.9 1.5 2.9 1 
two mixed fluorophores in the sample 
31 90 4.0 1.4 C.Blue-7FITC 
29 49 2.5 2.0 C.Blue-7 TRITC 
30 88 2.2 2.0 FITC-7C.Blue 
89 49 3.0 1.9 FITC-7TRITC 
31 48 3.0 2.8 TRITC-7C.Blue 
91 50 3.0 2.6 TRITC-7FITC 
three mixed fluorophores in the sample 
29 88 49 1.0 1.2 1.0 FITC-7C.B-7 TRITC 
29 90 50 4.8 4.7 4.4 C.B-7TRITC-7FITC 
31 87 47 3.5 2.5 3.5 RITC-7FITC-7C.B 
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Table 5.2.2 Fluorescence interference for a mixture of Cascade Blue, FITC and 
BODIPY. Concentrations of all fluorophores were kept in constant but the 
samples were measured under the different conditions which were same as in Table 
5.2.1. 
fl into C.Y. %n=6 measuring order 
C.B FITC BODI C.B FITC BODI 
single fluorophore in the sample 
50 38 25 I 4.3 3.2 1.0 I 
two mixed fluorophores in the sample 
49 38 7.6 5.5 FITC~C.Blue 
37 25 3.0 3.5 FITC~BODI 
48 37 4.0 5.7 C.Blue~FITC 
47 24 2.1 4.2 C.Blue~BODI 
39 26 5.4 2.3 BODI~FITC 
49 24 4.0 2.1 BODI~C.Blue 
three fluorophores mixed in the sample 
47 37 24 3.5 3.0 3.1 FITC~C.B~BODI 
46 38 23 2.5 2.7 3.6 C.B~BODI~FITC 
47 38 23 3.6 2.7 3.6 BODI~FITC~C.B 
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Table 5.2.3 Fluorescence interference for the mixture of Cascade Blue, FITC 
TRITC and Cy5. Concentrations of all fluorophores were kept in constant but the 
samples were measured under the different conditions which were same as in Table 
5.2.1. 
fl int. C.V. %n=6 measuring order 
C.B fitc trite Cy5 C.B fite trite Cy5 
single fluorophore in the sample 
60 38 20 46 I 3.2 2.0 2.2 4.0 I 
two mixed fluorophores in the sample 
59 40 4.1 2.8 C.B~fite 
61 22 3.0 3.8 C.B~tritc 
58 47 2.8 3.5 C.B~Cy5 
38 21 3.0 2.9 fite~tritc 
40 48 3.2 2.9 fite~Cy5 
60 37 2.8 4.0 fite~C.B 
19 46 4.5 3.8 trite~Cy5 
58 20 4.0 3.8 trite~C.B 
40 21 4.0 3.6 trite~fitc 
60 48 3.4 2.9 Cy5~C.B 
41 46 2.8 4.0 Cy5~fite 
19 48 3.8 2.9 Cy5~trite 
four fluorophores mixed in the sample 
60 40 19 47 3.0 2.9 4.0 3.6 C.B~fitc~tritc~Cy5 
59 41 20 48 3.3 3.6 4.5 2.9 fitc~tritc~Cy5~C.B 
58 39 20 49 4.0 3.8 2.9 3.4 tritc~Cy5~C.B~fitc 
61 41 21 47 4.0 3.6 2.9 4.0 Cy5~C.B~fitc~tritc 
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5.3 Analytes, Fluorophores and Conjugates Behaviour on the T-gel Solid 
Phase Column 
5.3.1 Insulin and Its Conjugates Behaviour on the T-gel Column 
Insulin is a well known drug for treating type I diabetes and is widely used in the 
clinical environment (chapter 1, 1.5.5). Insulin shows marked NSB to T-gel 
(Fig.3.2.3), but the fluorophores used do not (Fig.3.2.5-3.2.8). Therefore, 
different insulin conjugates were studied on the T -gel column for possible use in 
immunoassays. 
The absorbance of insulin conjugates was measured on a DV absorbance 
spectrometer and shows they have absorbance at two wavelengths, 280 nm 
(insulin) and the fluorophore's, the conjugates were passed through onto the T-gel 
column are shown in Fig.5.3.1-5.3.4. In the figures (Fig.5.3.1-5.3.4), the different 
fluorescent insulin conjugates were passed through the T -gel column producing a 
measurement on the F-4500 spectrometer, (slits 2.5/2.5 run, flow rate 2.0 mlImin). 
Peak (1) is bound peak (NSB) of the conjugate only, (2) is bound peak of the 
conjugate with anti-insulin, and (3) is bound peak of the conjugate with the 
antibody and unlabelled insulin. All the conjugates were found to show significant 
NSB to the T-gel, and so were not suitable for the development of insulin 
immunoassays on this particular solid phase column. 
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Fig.5.3.1 C.Blue-insulin conjugate passed through the T -gel column, 
ex/em = 410/430 nm, ( .,l. is shown where the binding buffer changing to the elution 
buffer). 
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Fig.5.3.2 TRITC-insulin conjugate passed through the T-gel column, 
ex/em = 550/575 nm. 
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Fig.5.3.3 Cy5-insulin conjugate passed through the T-gel column, ex/em = 
6451668 nm . 
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Fig.5.3.4 BODIPY-insulin conjugate passed through the T-gel column, 
ex/em = 540/570 nm. 
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5.3.2 Wellferon and its Conjugates Behaviour on the T-gel Column 
Wellferon is a new drug developed for treating HIV, and it has been directly 
labelled with Cy5 for the development of flow injection immunoassay using protein 
A [1-2]. The method for making the conjugate of Cy5-wellferon is briefly 
described below: 
1) 0.1 mg/m! of wellferon 1 m! (30 III of 3.39 mg/m! of stock wellferon was added 
to 970 III of carbonate buffer pH 9.3) was added to 1.0 mg Cy5, then reacted on a 
rolling stirrer for a one and half hours' at room temperature. 
2) a 10 m! Sephadex G 25 column was applied to purify the conjugate. 
Wellferon and its Cy5 conjugate were passed through the T -gel column, with the 
results show in Fig.5.3.5-5.3.6. 
From the Fig.5.3.5-5.3.6 it can be seen that both wellferon and the conjugate show 
significant NSB to the T -gel. Therefore the Cy-5-wellferon conjugate was not 
suitable for the development of wellferon immunoassay on this solid phase reactor. 
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Fig.5.3.5 Fluorescence profile of Wellferon on the T-gel column and measured on 
the F-4500 spectrometer. ex/em = 280/335 nm, slits 2.5/2.5 nm, flow rate 2.0 
mlImin. 
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Fig.5.3.6 Conjugate of Cy5-wellferon passed through the T -gel and measured on 
F-4500 spectrometer. ex/em = 645/668 nm, slits 2.5/2.5 nm, flow rate 2.0 mlImin. 
peak 1) is bound peak (NSB) of the conjugate only, peak area = 62. 2) is bound 
peak of the conjugate with the anti-wellferon, peak area = 111 and 3) is bound 
peak of the conjugate with the antibody and unlabelled wellferon, peak area = 59. 
Peak 4-6) were repeated of 1-3) but 5% CHAPS was added, the peak areas are 63, 
270, and 1670 respectively. 
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5.4. The Effect of Surfactant on the T-gel Column 
Trying to reduce NSB to the T-gel column, a surfactant (CHAPS) was used. 
Unfortunately CHAPS also affects antibody binding to the column, so further 
studies were undertaken. Fig.5.4.l shows the effect of CHAPS on NSB and 
antibody binding to the T-gel column. 
From the results it can be seen that: 
1) the maximum concentration of CHAPS added to the antibody was 5%, 
otherwise the immunoassay would be effected.' 
2) CHAPS was able to reduce the N~B, but some of material caused strong NSB 
e.g insulin, this might need a high concentration of CHAPS in the assay. Because 
the CHAPS effects antibody binding more than NSB, therefore no CHAPS was 
added to the assays. 
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Fig.5.4.l CHAPS effects antibody binding and reduces the NSB using T -gel 
measured on LS-50B, flow rate 2.0 mg/ml, slits 10/10 run. CHAPS was dissolved 
in deionised water. ab = anti-hydrocortisone-2l-HS was diluted to 1:20 using PBS 
buffer pH 7.4, exJem = 280/335 run, insulin = 1.0 mg/ml insulin was dissolved in 
PBS buffer, pH 7.4, ex/em = 280/335 run, cort-fitc = FITC-BSA-hydrocortisone-
2l-HS conjugate was diluted to 1:5 in PBS buffer, pH 7.4, ex/em = 495/525 nm. 
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5.5 Comparison of T -gel to Protein A 
During the project, it has found that some of the analytes e.g. insulin, wellferon and 
their conjugates could not be used with the T-gel, but the use of Protein A was 
possible. Also the binding ability of the antibodies were different between T -gel 
and Protein A. For these reasons, some of analytes, conjugates and antibodies 
were investigated on both of the T -gel and protein A solid phase reactors. These 
are shown in Fig.5.5.l-5.5.2 (see also Fig.5.3.1-5.3.6 and Fig.3.2.3). 
From above results it is clear that 
I) analytes (proteins and drugs) have more NSB to T-gel, (the reason is not clear 
yet, perhaps is the charges of the T-gel). 
2) antibody binds ability to T-gel or Protein A is depending on the individual 
antibody, this does not show any fi~ure in this thesis. Also Protein A columns 
based on more expensive materials than T -gel and requires pH changing in an 
immunoassay, but their very lower level of NSB makes them superior to T-gel 
column for most assays. 
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Fig.5.5.1 Same concentrations of 1) BSA, 2) insulin and 3) wellferon through the 
protein A solid column measured on F-4500 spectrometer. ex/em = 280/335 mn, 
slits 2.5/2.5 nm, flow rate 2.0 mlImin. 
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Fig.5.5.2 1) Cy5, 2) conjugates of Cy5-wellferon and 3) Cy5-insulin through 
protein A solid column measured on F-4500 spectrometer. ex/em 6451668 nm, 
slits 2.5/2.5 nm, flow rate 2.0 ml/min. 
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6.1 Conclusion 
Immunoassays are well known as analytical methods in clinical chemistry and other 
fields, being sensitive, safe, easy to use and available in a variety of formats. The 
immunoassays normally used in industry or research now are still mostly single 
assays, i.e. each assay is only able to analyse one analyte. But in many cases dual-
or multi-analyte assays would be much more valuable with the advantages of 
increased information content, savings in time and costs, and the elimination of 
some sources of sampling variance. Amongst all the labels used in immunoassays, 
only fluorescent groups offer realistic prospects of practicable multi-analyte assays. 
This project has developed single and dual analytes immunoassays, and 
investigated multi-analyte fluorescence spectroscopy techniques for the possible 
development of multi-analyte immunoassays. The immunoassays studied are based 
on competitive binding principles combined with flow injection analysis. The 
binding efficiency of T -gels and the advantages and disadvantages of solid phase 
immunoreactors based on T -gel and Protein A have also been studied. 
There was little difficulty in producing BSA and transferrin single immunoassays 
because the synthesis of the fluorescent protein conjugates need conventional 
techniques. Theophylline and hydrocortisone immunoassays which proved that the 
T -gel column is a capable solid phase immunoreactor. 
The hydrocortisone immunoassay was carried out using the carbodiimide method. 
Because hydrocortisone is a small molecule, it lacks a functional group (NH2, SH, 
CaOH) which can directly react with a fluorophore or protein. The synthesis of a 
steroid derivative containing an additional functional group (eOOH) which is 
capable of coupling with amino residues in a protein molecule is a necessary step. 
During the process the pH level, temperature, reaction time, and the ratio of 
hydrocortisone to the protein are well controlled. Hydrocortisone-21-HS, 
containing a carboxyl group capable of coupling with amino residues in a protein, 
was used to instead of hydrocortisone, and BSA was used as the carrier. The 
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hydrocortisone-21-HS protein conjugate was labelled with a fluorophore ( FITC or 
TRITC). 
The Quant+ computer program is a chemometric software package suitable for 
multicomponent spectroscopic analysis. It provides a choice of multivariate 
calibration algorithms, PCR (principal components regression), PLS 1 and PLS2 
(different partial least squares methods) and suite to quantify components of the 
spectra of mixtures. 
A mixture of Cascade Blue, FITC and TRITC was studied on the flow injection 
analysis system and the data analysed using the Quant+ program. It was found that 
the data from the time scan were not able to inspect the three mixed fluorophores 
in the sample due to their well separated spectra and the Quant+ program is also a 
software suitable for multicomponent analysis but with single spectrum or ones 
which has a strong overlap. 
Synchronous fluorescence spectroscopy provides a suitable technique for multi-
component analysis. A wavelength interval, /:;.A, of 10 nm provided reasonable 
fluorescence intensity and excellent separation of the signals from a mixture of 
Cascade Blue and FITC. Synchronous scanning spectroscopy combined with flow 
injection analysis for dual BSA and transferrin immunoassays provided a simple 
and reproducible method. But because only a manual pump was utilised during the 
project, the flow rate and the stopped flow time required precise control. 
The 3-D scanning spectroscopy technique provides another method for measuring 
the fluorescence of mixture, but the scanning takes a long time so when it is 
combined with a flow injection system the rate of analysis is slow and is not really 
suitable for flow injection immunoassay. 
The F-4S00IC program is a sensitive and quick technique for measuring a 
component in a mixture especially if a stopped flow period is not required. During 
the project a well mixed sample was measured on a unstopped flow stream and 
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scanned on a 0.67 cm long section, therefore there may be some unpure compound 
which would be interference to the fluorescence intensity of the acutely compound 
(e.g. FITC with TRITC) if their wavelengths are close. 
In the comparison of T -gel and protein A, T -gel has major advantages in that it is 
cheaper, and no pH change is required for antibody binding and elution. This 
would increase the range of available fluorophores. On other hand, greater NSB 
reduces the sensitivity in the immunoassays and limited the application of T -gels in 
some multi-analyte assays. Protein A has lower NSB which makes it superior to 
T-gel columns for most immunoassays. 
6.2 Further Work 
Protein A may be used as a solid phase reactor carry on the research in multi-
analyte of wellferon, insulin, hydrocortisone, and theophylline immunoassay (e.g. 
wellferon-CyS, hydrocortisone-RITC/BODIPY, theophylline-C.Blue, and insulin-
RITC/BODIPY). 
Further study of the wavelength interval "'A and the slit widths to optimise the 
synchronous scanning method for multi-analyte assays would also be valuable. 
This might increase fluorescence intensities and overcome the overlaps between 
some fluorophores with very similar wavelengths e.g. FlTC and TRITC, or FITC, 
TRITC and BODIPY. 
A stopped flow experiment might be considered with the F-4S00IC spectroscopy 
software. Again this will be of increased usefulness in cases when the fluorescent 
components have very similar wavelengths. 
To improve the sensitivity and reduce the error in flow injection analysis 
immunoassays, an automatic pump or automatic flow injection system is needed. 
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